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Zusammenfassung 
Die Gruppe der clostridiellen Neurotoxine (CNTs) besteht aus Tetanus Neurotoxin 
(TeNT) und den sieben serologisch unterschiedlichen Botulinus Neurotoxinen (BoNT/A-G). 
Sie werden als 150 kDa große, einkettige Proteine in Clostridium tetani, C. botulinum, 
C. butyricum und C. baratii produziert und gehören zu den bakteriellen AB Proteintoxinen. 
Die CNTs werden posttranslational in eine 50 kDa leichte Kette (LC; A-Teil) und eine 
100 kDa schwere Kette (HC; B-Teil) hydrolysiert, die durch eine Disulfid-Bindung und nicht 
kovalente Wechselwirkungen miteinander verbunden bleiben. Die HC besteht aus drei 
Domänen, der 50 kDa amino-terminalen Domäne HN, und zwei 25 kDa großen Domänen, 
HCN und HCC, aus welchen sich das carboxyl-terminale HC-Fragment zusammensetzt. Das 
HC-Fragment bindet hochspezifisch an Motorneurone und übernimmt die rezeptorvermittelte 
Endozytose der CNTs. Aufgrund der Ansäuerung der Endosomen insertiert die hydrophobe 
HN-Domäne in die Vesikelmembran und die LC entfaltet sich partiell, um in das Zytosol 
transluziert werden zu können. Dort angekommen wird die Disulfid-Bindung reduziert, und 
die freigesetzte LC, eine Zn2+-Endoprotease, kann spezifisch die Kernkomponenten der 
Vesikelfusionsmaschinerie hydrolysieren, so dass die Neurotransmitterfreisetzung 
unterbrochen ist. Die BoNTs blockieren die Azetylcholinfreisetzung in Motorneuronen, was 
zur Paralyse der Muskulatur führt (Botulismus). Im Gegensatz dazu wird TeNT in neutrale 
Vesikel sortiert und retrograd intraaxonal in inhibitorische Neuronen transportiert. Dort wird 
die Freisetzung von Glycin und γ-Aminobuttersäure (GABA) inhibiert, welches zu einer 
spastischen Paralyse der Muskulatur führt (Tetanus). Die hochspezifischen Interaktionen des 
HC-Fragments mit seinen Rezeptoren, Polysialinsäuregangliosiden und größtenteils unbe-
kannten Transmembranproteinen, sind auf molekularer Ebene nahezu unbekannt gewesen. 
Unter Berücksichtigung der dreidimensionalen Struktur der CNTs wurden mittels 
zielgerichteter Mutagenese zwei Gangliosidbindungstaschen in TeNT und eine dazu 
homologe Stelle in BoNT/A und B identifiziert und detailliert charakterisiert. Die homologe 
Gangliosidbindungstasche ist in fast allen Serotypen konserviert und besteht aus folgendem 
Peptidmotiv: D/E….H….SXWY….G. Die Mutation einer einzigen Schlüsselaminosäure wie 
z.B. des Tryptophans führt zu einer drastischen Verminderung der Neurotoxizität von >95% 
im Mauszwerchfell-Testsystem. Massenspektroskopische Untersuchungen zeigten, dass 
BoNT/A und B lediglich ein einziges Gangliosidmolekül binden, während TeNT deren zwei 
koordiniert. Dies wäre ein Erklärungsansatz für die unterschiedliche Sortierung von TeNT 
und BoNTs im Motorneuron. BoNT/B benutzt die intravesikuläre Domäne der synaptischen 
Vesikelproteine Synaptotagmin I und II als zweiten Rezeptor. Das nahe verwandte BoNT/G 
zeigte ebenfalls eine Interaktion mit denselben Proteinabschnitten in GST-pull-down 
Experimenten. Die Neurotoxizität von BoNT/B und G im Mauszwerchfell Testsystem wurde 
durch Zugabe eines Peptids identisch zur intravesikulären Domäne von Synaptotagmin I bzw. 
II neutralisiert. Das Wissen der molekularen Interaktion der zwei Rezeptortypen innerhalb der 
HCC-Domäne von BoNT/B und G versetzt den Fachmann damit in die Lage, einen 
hochaffinen, zweizähnigen Liganden zu konstruieren, welcher als Antagonist für akute BoNT 
Intoxikationen eingesetzt werden könnte. 
Schlagworte: Botulinus Neurotoxin, Tetanus Neurotoxin, Gangliosid, HC-Fragment, Rezeptor 
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Abstract 
The group of clostridial neurotoxins (CNTs) consists of tetanus neurotoxin (TeNT) 
and the seven botulinum neurotoxin serotypes (BoNT/A-G). They are produced as 150 kDa 
single chain proteins by Clostridium tetani, C. botulinum, C. butyricum and C. baratii and 
belong to the bacterial AB protein toxins. The CNTs are posttranslationally hydrolysed into a 
50 kDa light chain (LC; A-unit) and a 100 kDa heavy chain (HC; B-unit) which remain 
associated via a disulfide bond and non-covalent interactions. The HC is composed of three 
domains, a 50 kDa amino-terminal domain (HN), and two 25 kDa domains, HCN and HCC, 
constituting the carboxyl-terminal HC-fragment. The HC-fragment binds specifically to 
motoneurons and mediates uptake of the CNTs via receptor mediated endocytosis. Upon 
acidification of the endosome the HN-domain inserts into the membrane, the LC partially 
unfolds and is translocated into the cytosol. Here, following reduction of the disulfide bond 
the LC acts as Zn2+ dependent endoprotease specifically hydrolysing the core components of 
the vesicular fusion machinery thereby abrogating neurotransmitter release. While BoNTs 
block acetylcholine release in the motoneuron resulting in flaccid paralysis (botulism), TeNT 
is sorted into vesicles with neutral pH and intraaxonal retrogradely transported to inhibitory 
neurons to block glycine and γ-aminobutyric acid (GABA) release resulting in spastic 
paralysis (tetanus). The molecular understanding of the highly specific interaction of the 
HC-fragment with its receptors, polysialo gangliosides and predominantly unidentified 
transmembrane proteins, is unknown. Rational site directed mutagenesis employing three 
dimensional structures of CNT HC-fragments led to the identification and characterisation of 
two ganglioside binding sites in TeNT and one homologous pocket in BoNT/A and B. The 
homologous ganglioside binding pocket is mainly conserved throughout the CNTs and is 
formed by a D/E….H….SXWY….G peptide motif. Mutation of a single key residue like the 
tryptophane leads to a loss of more than 95% in neurotoxicity at mice phrenic nerve 
preparations. According to mass spectroscopy experiments BoNT/A and B bind only a single 
ganglioside molecule while TeNT bounds two of them. This may imply a reason for the 
different sorting of TeNT and BoNTs. Further on, BoNT/B employs the intravesicular domain 
of the synaptic vesicle protein synaptotagmin I and II as second receptor. The homologous 
BoNT/G was shown to interact similarly with synaptotagmin I and II in GST-pull-down 
assays. The neurotoxicity of BoNT/B and G in the mice phrenic nerve assay could be 
neutralised by addition of the intravesicular domain peptide of synaptotagmin I and II. The 
dual receptor interactions of BoNT/B and G occur in the HCC-domain which would allow the 
design of potent bidentate binding inhibitors as antagonist for acute BoNT intoxication. 
Keywords: Botulinum neurotoxin, Tetanus neurotoxin, ganglioside, HC-fragment, receptor 
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Abbreviations 
α-SNAP    α soluble NSF attachment protein 
a     year 
aa     amino acid 
ACE     angiotensin converting enzyme 
BoNT/A-G    botulinum neurotoxin A-G 
bp     base pair 
BSA     bovine serum albumin 
C. botulinum    Clostridium botulinum 
CD     circular dichroism 
CDC     Centers for Disease Control and Prevention 
Cer     ceramide 
CHO     Chinese hamster ovary 
CMC     critical micellar concentration 
CNT     clostridial neurotoxin 
CT     cholera toxin 
Da     Dalton 
DNA     desoxyribonucleic acid 
E. coli     Escherichia coli 
Gal     galactose 
FDA     Federal Food and Drug Administration 
GABA     γ-aminobutyric acid 
GD1a     NAcNeuα3Galβ3NAcGalβ4(NAcNeuα3)Galβ4GlcβCer 
GD1b     Galβ3NAcGalβ4(NAcNeuα8NAcNeuα3)Galβ4GlcβCer 
GD3     NAcNeuα8NAcNeuα3Galβ4GlcβCer 
Glc     glucose 
GM1     Galβ3NAcGalβ4(NAcNeuα3)Galβ4GlcβCer 
GM3 NAcNeuα3Galβ4GlcβCer 
GPI glycosylphosphatidylinositol 
GQ1b NAcNeuα8NAcNeuα3Galβ3GalNAcβ4 
(NAcNeuα8NAcNeuα3) Galβ4GlcβCer 
GT1b NAcNeuα3Galβ3GalNAcβ4(NAcNeuα8NAcNeuα3) 
Galβ4GlcβCer 
GST     glutathion-S-transferase 
GT-sepharose    glutathion-sepharose 
HA     hemagglutination activity 
HC     100 kDa heavy chain of clostridial neurotoxins 
HC     50 kDa carboxyl-terminal fragment of heavy chain 
HCC     25 kDa carboxyl-terminal domain of HC-fragment 
HCN     25 kDa amino-terminal domain of HC-fragment 
HN     50 kDa amino-terminal fragment of heavy chain 
HEPES    4-(2-hydroxyethyl)-1-piperazinethansulfonic acid 
HPLC     high performance liquid chromatography 
IPTG     iso-propyl-1-thio-ß-D-galactopyranoside 
Lac     lactose, 4-O-β-D-galactopyranosyl-D-glucose 
LC     50 kDa light chain of clostridial neurotoxins 
LMW     low molecular weight 
LT     E. coli heat-labile enterotoxin 
Lubrol     polyoxyethylen-9-laurylether 
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MALDI-TOF matrix assisted laser desorption and ionisation – time of 
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MNT     maternal and neonatal tetanus 
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mRNA    messenger ribonucleic acid 
MS     mass spectroscopy 
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NAcNeu    N-acetyl-neuraminic acid, sialic acid 
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RBS     ribosome binding site 
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SDS     sodium dodecylsulfate 
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SNARE    soluble NSF attachment protein receptor 
Syb     synaptobrevin, q.v. VAMP 
Syt     synaptotagmin 
TeNT     tetanus neurotoxin 
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Introduction 
Introduction 
The group of clostridial neurotoxins (CNTs) consists of tetanus neurotoxin (TeNT) 
and the seven botulinum neurotoxin serotypes (BoNT/A-G). They are produced by 
Clostridium tetani, C. botulinum, C. butyricum and C. baratii and belong to the bacterial AB 
protein toxins. Their minimal lethal doses (MLD) range down to subnanogram amounts per 
kg body weight (Gill, 1982); consequentially they are the most potent natural toxins known. 
Clostridial neurotoxins cause tetanus and botulism 
Tetanus (Greek: to contract) was already described by Hippocrates 400 B.C., but not 
until the beginning of the 19th century the disease botulism (Latin: botulus, sausage) was 
recognised to be caused by a toxin derived from sausages (Kerner, 1817). The toxin’s 
bacterial origin remained in the dark for almost another hundred years (van Ermengem, 1897; 
Burke, 1919). 
The disease tetanus 
Tetanus is caused by germination of Gram-positive, anaerobic spore-forming 
Clostridium tetani in infected tissue lesions. The bacteria start producing TeNT which is 
released into the blood stream and reaches the neuromuscular endplate via the circulation. 
After uptake into motoneurons TeNT is transported retrogradely to inhibitory neurons and 
blocks the release of glycine or γ-aminobutyric acid (GABA) which results in spastic 
paralysis of the muscles. 
 
Fig. 1: Neonatal tetanus of a two week old baby (WHO et al., 2000) 
Thorough immunisation of the population with tetanus toxoid has nearly eradicated 
tetanus in industrialised countries (2 cases per 10 million inhabitants). In contrast, especially 
maternal and neonatal tetanus (MNT) remains endemic in the developing world. The World 
Health Organization (WHO) estimated that there were approximately one million deaths from 
tetanus worldwide in 1992. This included 580,000 deaths from neonatal tetanus, of which 
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210,000 were in South East Asia and 152,000 in Africa. In 1998, despite of the WHO’s 
attempt to eliminate MNT, in 57 countries of the developing world approximately 289,000 
cases of neonatal tetanus led to the death of 215,000 newborns (75% fatality rate; 14% of all 
newborns deaths) and 30,000 mothers died of maternal tetanus, while only one case of tetanus 
in newborns was reported in the U.S.A. (WHO et al., 2000). 
The disease botulism 
In contrast, botulism is described by flaccid paralysis of the muscles because the 
BoNTs remain in the motoneuron after uptake and inhibit the acetylcholine release. Four 
clinical forms of botulism occur in humans: food borne botulism, wound botulism, infant 
botulism (infant intestinal colonisation) and, rarely, adult infectious botulism (adult intestinal 
colonisation). Food borne as well as the rare inhalation botulism is evoked by ingestion of 
food respectively aerosols containing BoNT progenitor toxins. Spores of various strains of 
C.botulinum, C.butyricum and C.barati germinate well in contaminated food under anaerobic 
conditions and the bacteria produce acid and protease resistant BoNT progenitor toxins. After 
passage of the gastrointestinal tract, resorption in the intestine and disassembly, the pure 
BoNT reaches the neuromuscular endplate via the circulation. Wound botulism is caused by 
germination of spore-forming C. botulinum in infected tissue lesions, nowadays preferably 
upon contaminated injections in drug addicts, leading to the release of BoNT progenitor toxin 
directly into the blood stream. 
 
Fig. 2: Infant botulism (Simpson, 1989). 
Adult and the more frequent infant intestinal botulism are caused upon the ingestion of 
spores and subsequent colonisation of the intestine with C. botulinum. Especially the infants’ 
intestinal flora is very immature during the first six postnatal months allowing an easy 
colonisation. About 10% of the cot death cases seem to be related to infant botulism. A main 
source of C. botulinum spores is honey. The BoNT progenitor toxin is released directly from 
the bacteria into the gut and is subsequently resorbed. Due to the increasing number of 
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treatments with pharmaceutical compositions of BoNT, the risk of overdoses also leads to a 
few cases of botulism. 
From 1989 through 2003 the 1,800 notified cases of botulism in the U.S.A. led to only 
21 deaths. Due to high hygienic standards and clinical treatment the overall fatality rate of 
botulism decreased from 50% to <5% in industrialised countries in the last 60 years. In the 
developing world, botulism still remains a severe threat due to lack of hygiene and rare 
detection of symptoms followed by appropriate therapeutic treatment. 348 cases of food borne 
botulism (19.3%; average 23 cases/a; range 8-86 cases/a; fatality rate 7%), 225 cases of 
wound botulism (12.5%; average 15 cases/a; range, 0-30 cases/a, fatality rate 10%), 12 cases 
of adult infectious botulism (0.7%; average 1 case/a; range, 0-3 cases/a), 1211 cases of infant 
botulism (67.3%; average 81 cases/a; range, 50-104 cases/a, fatality rate <2%) and 7 cases of 
botulism of undetermined type were reported to the Centers for Disease Control and 
Prevention (CDC) in Atlanta, GA (Maslanka and Sobel, 2000-2004). In the U.S.A., 55% of 
food borne botulism are caused by BoNT/A and 35% by BoNT/E; the remaining food borne 
cases are almost equally divided between BoNT/B and F. Among cases of wound botulism, 
approximately 95% are caused by BoNT/A and 5% by BoNT/B while 40% of infant botulism 
are caused by BoNT/A and 69% by BoNT/B (Maslanka and Sobel, 2000-2004). BoNT/C1 
and D do not initiate human food borne botulism but cause botulism in wildlife and domestic 
animals. Especially in hot summers outbreaks of avian botulism caused by BoNT/C1 are 
observed. However, humans are thought to be susceptible to these serotypes because they 
have caused botulism in primates (Gunnison and Meyer, 1930). BoNT/C1 has recently been 
shown to affect humans similarly to BoNT/A and B with respect to dose, mode and duration 
of action (Eleopra et al., 2004). BoNT/G, produced by a bacteria species discovered in South 
American soil in 1969 (Giménez and Ciccarelli, 1970), has never been described to cause 
food borne botulism. The species differences in BoNT toxicity may be due to the individual 
compositions of progenitor toxins or different binding affinities to diverse distributed cell 
surface receptors. Despite these disagreements, the symptoms of intoxications by the various 
serotypes of BoNT closely resemble each other, because of a similar mode of action. 
However, there might be differences in the degree peripheral nerves are affected. Depending 
on the serotype and the dose ingested, the disease may last from a few days to several months. 
Intoxication with BoNT/A has the longest duration of three to six months, whereas a patient 
poisoned with BoNT/E, even if it is a high dose, will recover within a few days. Recovery 
occurs when the catalytic domain of the neurotoxin inside the nerve ending is degraded to 
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inactive fragments and membrane fusion will be reactivated (Erdal et al., 1995; Adler et al., 
2001; Fernandez-Salas et al., 2004). 
Application of BoNTs - a janus-faced molecule 
Use of BoNTs as pharmaceuticals 
In the beginning of the 1970s crystalline BoNT/A complex was successfully tested by 
the surgeon Alan B. Scott and the microbiologist Edward J. Schantz for the treatment of 
hyperactive muscle disorders in monkeys and human beings (Scott, 1980; Schantz and 
Johnson, 1992). In December 1989 the BoNT/A complex, marketed as BOTOX®, was 
approved as orphan drug by the Federal Food and Drug Administration (FDA) to treat two 
eye muscle disorders (blepharospasm and strabismus). BOTOX® as well as the BoNT/B 
complex (Neurobloc®/Myobloc®) were approved in 2000 to treat cervical dystonia, a 
neurological movement disorder causing severe neck and shoulder muscle contractions. In 
2002 BoNTs were approved as a cosmetic to temporarily improve the appearance of moderate 
to severe frown lines between the eyebrows and in 2004 to treat severe underarm sweating 
known as “primary axillary hyperhidrosis” (www.fda.gov). Subsequently, the American 
Society of Aesthetic and Plastic Surgery estimated that 2.27 million BoNT treatments were 
performed in the U.S.A. in 2003, which makes the BoNT market to be worth more than $ 900 
million in 2003. Other BoNT/A complex preparations on the current world market include 
Dysport® (Ipsen, Inc., UK, to be marketed in the U.S. as Reloxin®, Inamed, Inc. early 2006), 
Linurase® (Prollenium, Inc., Canada), and an assortment of preparations from Asia, including 
CBTX-A® (Lanzhou Biological Products Institute, VR China), and Neuronox® (Medy-Tox, 
Inc., South Korea). Mentor Corporation plans to introduce a highly purified BoNT/A 
preparation (free of complex proteins) for cosmetic use in the U.S.A. in 2006, and a similar, 
highly purified BoNT/A (NT201/Xeomin®, Merz Pharma GmbH, Frankfurt/M.) was 
approved in Germany in June 2005. At present, more than 100 clinical applications are 
described for BoNT therapy and clinical trials investigate the use of BoNTs in migraine and 
pain. This rapid development highlights the importance to complete the basic knowledge of 
the mechanism of BoNTs action. 
The misuse of BoNTs as biological warfare agent 
Another application of BoNT was fortunately banned in 1972 by a United Nations’ 
convention: the use for biological warfare. Nevertheless, although nearly 140 countries have 
signed the treaty, the former U.S.S.R as well as Iraq continued to produce BoNT/A as 
biological warfare agent. After the 1991 Persian Gulf War, Iraq admitted to the United 
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Nations’ inspection team to having produced 19 m3 of concentrated BoNT/A, of which 
approximately 10 m3 were loaded into military weapons. These 19 m3 of concentrated 
BoNT/A solution constitute approximately three times the theoretical amount needed to kill 
the entire current human population by inhalation (UN, 1995). Apart from state driven 
biological warfare the threat of bioterror attacks has dramatically heightened in the last decade 
terrorizing populations with toxins, causing panic and possible loss of lives. In 1990 the 
Japanese sect, Aum Shinrikyo, unsuccessfully dispersed aerosols containing BoNT and spores 
of bacillus anthracis at various locations in Japan (Wilkening and Seth Carus, 1998). In 
autumn 2001, in view of the terror attack of 11th September, letters containing spores of a 
laboratory bacillus anthracis strain were sent out to U.S. media personalities and politicians 
causing 22 incidences of anthrax poisoning, of which 19 cases had been confirmed claiming 
five lives and three cases had been suspected (Thompson, 2003). Later, the arrest of several 
Arabs with connections to the terror network of al quaida, who were trying to produce ricin 
toxin in northern London, was reported in January 2003. In light of these occurrences a 
theoretical model of a bioterror attack adding BoNT into the milk supply chain revealed that 
only 10 g of BoNT/A almost certainly leads to a loss of 500,000 lives (Wein and Liu, 2005). 
Theoretically, 10 g of BoNT/A are sufficient to kill 100 million adults. This illustrates the 
omnipresent threat by biological weapons and the need of research to take effective 
countermeasures such as screening for effective antagonists or improving detection systems. 
Taxonomy of C. botulinum  
The traditional classification of BoNT producing C. botulinum into seven strains (A-
G) was determined by neutralisation with specific antitoxin. However, all CNTs releasing 
clostridia were first divided into seven different groups upon their diverse phenotypes and 
sequencing of the 16S RNA supported this classification (Tab. 1). Within one group the 16S 
RNA is 99.6-100% identical (Collins and East, 1998). Meanwhile, the whole genomes of 
C. tetani and C. botulinum Hall strain A (ATCC 3502) are deciphered allowing a systematic 
investigation of the organism in a proteomic approach (Brüggemann et al., 2003); 
http://www.sanger.ac.uk/Projects/C_botulinum). The known nucleotide sequences of all 
CNTs exhibit i.a. a different localisation of the NT coding genes as well as a high A/T content 
(70%) typical for Clostridium. Furthermore, the CNTs share an aa homology of about 35% 
which points towards a horizontal gene transfer of the CNT encoding genes between the 
different groups of Clostridia (Minton, 1995). 
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Table 1: Groups of CNT producing Clostridia. 
Species Group CNT produced Proteolysis Localisation of CNT gene
Clostridium botulinum I A, B, F + chromosome 
Clostridium botulinum II B, E, F - chromosome 
Clostridium botulinum III C1, D - bacteriophage 
Clostridium botulinum IV G + plasmid 
Clostridium butyricum V E - chromosome 
Clostridium baratii VI F - chromosome 
Clostridium tetani  TeNT + plasmid 
 
Fig. 3: Dendogram showing the phylogenetic differences of the 17 main CNT variants on 
the aa level (http://align.genome.jp). 
It should be noted that the degree of similarity between CNTs variants differs 
significantly from the grouping of the host organisms (cp. Tab. 1 and Fig. 3). Furthermore, the 
neurotoxin encoding genes themselves seem to be assembled from sections of different 
sources (Niemann et al., 1994). 
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BoNT progenitor toxins 
The MLD of BoNTs dramatically depends on i.a. their molecular composition. E.g., 
pure BoNT/A is about a factor 100,000 less toxic than the BoNT/A progenitor toxin by the 
oral route. The reason for this contradictory behaviour rests on the sophisticated assembly of 
the BoNT progenitor toxins released by C. botulinum. Upstream of the genes encoding the 
BoNTs, an open reading frame (ORF) for a 150 kDa protein and up to three ORFs for 
17-70 kDa proteins with hemagglutination activity (HA) were found (Fig. 4). 
 
Fig. 4: Diagrammatic representation of the arrangement of genes encoding the 
progenitor toxin proteins consisting of BoNT, NTNH and HA (Collins and East, 1998). 
The 150 kDa protein, called non-toxic non-hemagglutination (NTNH) protein, forms a 
300 kDa complex with the BoNTs. This complex is one of the three forms of progenitor 
toxins known: the 12S M-Toxin (~280 kDa), consisting of one BoNT and one NTNH 
molecule; the 16S L-Toxin (~400 kDa), formed by association of M-Toxin with the three HA 
subcomponents, and the 19S LL-Toxin (~900 kDa) is composed of a homodimer of L-Toxin 
linked by HA-33. Accordingly, the L- and LL-Toxins exhibit hemagglutination activity, but 
the M-Toxin does not. However, the number of each HA subcomponent responsible for 
hemagglutination activity remains undetermined (Fujii, 1995). While BoNT/A occurs in all 
three different molecular forms, BoNT/C1 and D appear as L- and M-Toxins. BoNT/G is 
exclusively found as L-Toxin and BoNT/E and F are entirely composed of M-Toxin. The 
progenitor toxins, which are resistant to proteases and acids, dissociate immediately at 
physiological pH into neurotoxin and non-toxic components (Minton, 1995; Fujii, 1995). 
Thus, upon ingestion of the BoNT progenitor toxin, the protein complex resists the low pH in 
the stomach as well as the attack of pancreatic enzymes in the upper small intestine before it 
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is absorbed in the lower intestine. The HA proteins seem to act as adhesins, allowing the 
progenitor toxin to bind to intestinal epithelial cells and erythrocytes (Nishikawa et al., 2004; 
Fujinaga et al., 2004) most likely via terminal galactose molecules. 
If pure BoNT/A is ingested, however, the neurotoxin loses most of its toxicity, 
because it is almost completely destroyed during the digestive tract passage. The same might 
be true if the neurotoxin is inhaled, because the surface of the mucous membrane in the lung 
is rich in protease activity. The pure neurotoxin does not lose its toxicity when applied 
parenterally, e.g. intraperitoneally, because a protection against proteases is not required in 
that case. For humans the calculated MLD of pure BoNT/A is approximately 0.3 ng/kg after 
intravenous application, 20 ng/min/m3 after inhalation and 1 µg/kg following ingestion. These 
numbers allow only a rough estimation and were partly deduced from experiments with 
rodents (Cardella, 1964) and accidental intoxications in human (Naumann and Moore, 2003). 
Experiments with primates showed a higher toxicity, when BoNT entered the organism via 
the respiratory route (Franz et al., 1993). 
Three dimensional structure of CNTs 
The elucidation of the crystal structures of BoNT/A and B (Lacy et al., 1998; 
Swaminathan and Eswaramoorthy, 2000) illustrates that most likely all CNTs are composed 
of four functionally independent domains that perform individual tasks in the multi-step 
intoxication process (Fig. 5). 
All CNTs are produced as ~150 kDa single chain (sc) proteins. A surface exposed 
peptide loop of eight to 27 aa, rich in lysine and arginine residues and framed between two 
cysteines, is posttranslationally hydrolysed either by clostridial or foreign host proteases (cp. 
Tab. 1). This process called nicking generates a ~100 kDa heavy chain (HC) and a ~50 kDa 
light chain (LC). Both chains remain associated by a single disulfide bond, which is bypassing 
the cleaved loop between LC and HC, non-covalent interactions and an HC derived peptide 
loop, called belt, wrapping around the LC. The HCs or B-units are responsible for 
neurospecific binding and uptake of the molecule for translocation of their LCs into the 
cytosol. The globular folded LC represents the catalytic domain or A-unit cleaving soluble 
NSF attachment protein receptor (SNARE) proteins. The HC is separated into the amino-
terminal 50 kDa HN domain and the carboxyl-terminal 50 kDa HC-fragment. The HN domain 
is highly α-helical and contains predominantly hydrophobic residues which are believed to be 
involved in the translocation step. 
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Fig. 5: Crystal structure of native BoNT/B (1EPW.pdb; top) and schematic domain 
arrangement of CNTs (bottom). 
The crystal structure analysis of the TeNT HC-fragment identified two 25 kDa 
domains within HC, an amino-terminal lectin-like jelly-roll domain (HCN, residues 865-1110) 
and a carboxyl-terminal β-trefoil domain (HCC, residues 1110-1315) (Umland et al., 1997; 
Knapp et al., 1998). In a sequence and structural alignment study within the less conserved 
HCC domains of TeNT and BoNT/A, B, E, F, and G (23% aa sequence similarity on average), 
12 structurally conserved regions, each of five residues, were identified as β-trefoil forming 
segments; 44 of these 60 amino acids are highly conserved (Ginalski et al., 2000). This 
sequence homology was confirmed by the tertiary structure found in the crystals of BoNT/A 
and B (Lacy et al., 1998; Swaminathan and Eswaramoorthy, 2000). The characteristics of β-
trefoil folds allow a high sequence variation outside the 12 five aa clusters (cp. Tab. 2). 
Accordingly to the four domain structure, LC, HC and HC can be easily isolated as 
native/clostridial derived proteins by proteolysis and chromatography while the HN domain is 
very insoluble. Upon recombinant expression of CNTs in E. coli, only LC and HC-fragments 
are isolated in high yields, but hardly HC and HN (Rummel Diplomarbeit, 1999). 
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Mode of action of CNTs 
Following entry of the CNT into the circulation, the HC-fragment specifically binds to 
glycolipid receptors on the surface of neuronal cells (Fig. 6). Subsequent internalisation via 
receptor-mediated endocytosis brings the BoNTs into the endosomal compartment of 
motoneurons (Bigalke and Shoer, 2000). Here, an acidic environment below pH 6.5 (M. 
Montal, personal communication) allows the structural rearrangement and concomitant 
insertion of the HN-domain into the endosomal membrane. At the same time the LC is 
partially unfolded (Koriazova and Montal, 2003). Upon reduction of the disulfide bond, the 
LC functions as a Zn2+ dependent endopeptidase in the cytosol. TeNT is sorted in neutral 
vesicle and transported retrogradely to inhibitory neurons where a similar mechanism occurs. 
 
Fig. 6: Mode of action of BoNTs at the cholinergic motoneuron 
(modified from Arnon et al., 2001). 
CNT LCs specifically cleave SNARE proteins 
CNT LCs exclusively hydrolyse members of the three SNARE families. VAMP 
(vesicle associated membrane protein)/synaptobrevin represents the substrate for BoNT/B, D, 
F, G, and TeNT, whereas BoNT/A, C, and E cleave SNAP-25 (synaptosome associated 
protein of 25 kDa) (Fig. 7). Except for BoNT/B and TeNT, which share the same cleavage 
site, hydrolysis occurs at unique positions. BoNT/C1 is additionally capable of hydrolysing 
syntaxin1A. Cleavage of any neuronal SNAREs results in inhibition of the fusion of synaptic 
vesicles with the presynaptic membrane, thus a blockade of neurotransmitter release 
(Niemann et al., 1994; Schiavo et al., 2000). 
 10
Introduction 
 
Fig. 7: The SNARE proteins are specific substrates for the CNT LCs. Schematic 
drawing of the SNARE proteins structure and LC cleavage sites (top). 
Crystal structure of the coiled coil bundle of the core SNARE complex 
(bottom; modified from R.B. Sutton et al., 1998). 
All LCs contain a conserved HExxH motif, typical for Zn2+ metalloproteases as 
thermolysin and angiotensin converting enzyme (ACE). Two histidine residues and a 
conserved glutamate further downstream coordinate the zinc cation, while the glutamate in the 
HExxH motif positions a water molecule for hydrolysis into the empty coordination space of 
zinc. In case of BoNT/A, the conserved R362 and Y365 are also directly involved in the 
catalytic mechanism (Binz et al., 2002). Recently, the cocrystal structure for BoNT/A LC and 
its substrate SNAP-25 was solved, visualising the extensive enzyme-substrate interaction 
surface which explains their high specificity (Breidenbach and Brunger, 2005). 
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Gangliosides as receptors for CNTs 
The specific binding to peripheral nerve endings at the neuromuscular junction solely 
involves the 50 kDa carboxyl-terminal half of the HC, the HC-fragment (Simpson, 1984a; 
1984b; 1985; Evinger and Erichsen, 1986; Fishman and Carrigan, 1987; Lalli et al., 1999) and 
complex polysialo gangliosides, glycosphingolipids that are found particularly in membranes 
of neuronal cells (van Heyningen and Miller, 1961; Simpson and Rapport, 1971a). The 
interaction of gangliosides with CNTs was investigated for TeNT and several serotypes of 
BoNTs in extensive studies (Halpern and Neale, 1995; Yowler and Schengrund, 2004). These 
studies revealed that the disialo carbohydrate structure as found in GD1b is essential for the 
binding of most of the CNTs. Furthermore, it was shown that TeNT, BoNT/A, B, C, E, and F 
displayed affinities in the high nM range in various in vitro binding assays with immobilised 
polysialo gangliosides, whilst binding experiments of CNTs to neuronal tissue like 
synaptosomes revealed much higher affinities (KD = 1.2 nM). 
 
Fig. 8: Ganglioside biosynthesis. Disruption of the GalNAc-transferase gene in mice 
results in the absence of all the complex gangliosides within the dashed rectangle 
(Takamiya et al., 1996). 
At the cellular level, the cleavage of sialic acid residues by neuraminidase treatment of 
cultured cells isolated from spinal cord (Bigalke et al., 1986) and adrenergic chromaffin cells 
(Marxen et al., 1989) was shown to reduce BoNT/A potency as well as TeNT action 
(Critchley et al., 1986). Conversely, bovine chromaffin cells lacking the complex polysialo 
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gangliosides were rendered sensitive to TeNT and BoNT/A by incubation with gangliosides 
(Marxen et al., 1989; Marxen et al., 1991). In addition, a monoclonal antibody to GT1b was 
shown to antagonize the action of BoNT/A on rat superior cervical ganglion neurons (Kozaki 
et al., 1998). Recently, the inhibition of ganglioside biosynthesis with fumonisin in primary 
spinal cord neurons and with PPMP in the neuroblastoma cell line Neuro2a resulted in 
insensitivity to TeNT and BoNT/A, respectively (Williamson et al., 1999; Yowler et al., 
2002). 
Employing a genomic approach, mice, deficient in NAcGal-transferase thus only 
expressing GD3 (Fig. 8), were reported to resist treatment with TeNT and BoNT/A, B and E 
(Kitamura et al., 1999; Bullens et al., 2002), whereas GD3-synthetase knock-out mice lacking 
GD2, GD1b, GT1b and GQ1b were only resistant to TeNT but kept their sensitivity towards 
BoNT/A, B and E (Kitamura et al., 2005). Hence, complex polysialo gangliosides like GD1a, 
GD1b and GT1b play an important role in mediating the first cell contact and for the specific 
binding to neuronal cells. 
Postulation of a protein as second receptor for CNTs 
Nevertheless, the discrepancy in affinity between binding of CNTs to isolated 
gangliosides and neuronal tissue prompted postulations of a second receptor component. The 
protease-sensitive binding of BoNT/A and TeNT to rat brain synaptosomes (Kitamura, 1976; 
Dolly et al., 1982; Pierce et al., 1986; Lazarovici and Yavin, 1986) resulted in a dual receptor 
model. First, the polysialo gangliosides were considered to accumulate CNTs on the plasma 
membrane surface. Then, the CNTs simply wait in that position until binding to their thinly 
distributed protein receptor(s) is enabled or move laterally within the membrane while still 
bound to low affinity receptors thereby increasing the chance of contact with the protein 
receptor. Simultaneous interaction with ganglioside and protein receptor may be considered as 
high affinity binding and be prerequisite for the subsequent specific step of endocytosis 
(Montecucco, 1986; Niemann et al., 1991). 
Several studies demonstrated accelerated uptake of TeNT (Simpson, 1985) and 
BoNT/A (Black and Dolly, 1986) upon electrical stimulation into hemidiaphragm 
preparations as well as of BoNT/A and E upon K+ stimulation into spinal cord neurons (Keller 
et al., 2004). Also an earlier onset of the blockade of neurotransmission on nerve stimulation 
upon application of BoNT/A (Hughes and Whaler, 1962) and TeNT (Schmitt et al., 1981) 
was observed. As nerve stimulation causes increased rates of exo- and endocytosis of synaptic 
vesicles, one can assume that synaptic vesicle proteins, which become temporarily exposed on 
the cell surface at the synaptic cleft upon neurotransmitter release, are involved in the binding 
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and uptake of CNTs. Indeed, the synaptic vesicle membrane protein synaptotagmin (Syt)-I 
fulfilling these criteria (Perin et al., 1990; Geppert et al., 1991) was identified as BoNT/B 
interacting protein of rat brain synaptosomes employing cross-linking experiments (Nishiki et 
al., 1993; Nishiki et al., 1994). The current 13 isoforms of the Syt family are supposed to 
trigger vesicular fusion upon Ca2+ entry (Chapman, 2002; Südhof, 2002). The recombinant 
isoforms Syt-I and Syt-II incorporated in GD1a or GT1b endowed liposomes interacted in 
vitro with BoNT/B (Nishiki et al., 1996b) as well as Syt-II stably expressed in CHO cells 
(Nishiki et al., 1996a). Use of recombinant deletion mutants of Syt-II demonstrated that only 
the amino-terminal domain, which is extracellularly exposed upon exocytosis, plus the 
transmembrane region retains BoNT/B binding activity (Kozaki et al., 1998). Recently, the 
finding that Syt-I and Syt-II mediate the entry of BoNT/B was confirmed by means of loss-of-
function and gain-of-function approaches employing PC12 cells. Furthermore, results of 
GST-pull-down assays narrowed the BoNT/B binding segment of Syt-I and Syt-II down to 
the 20 juxtamembrane aa of the intravesicular domain. A peptide derived of the Syt-II 
interacting segment blocked uptake of BoNT/B at rat phrenic nerve-hemidiaphragm motor 
terminals. It also neutralized the toxicity in mice when administered together with 
gangliosides. Neither binding of BoNT/A and E to Syt-I and Syt-II nor their uptake were 
observed (Dong et al., 2003). 
The diverse sites of action of BoNTs and TeNT, leading to truly opposite symptoms, 
are caused by a different sorting of BoNTs and TeNT after their uptake into presynapses at 
the neuromuscular junction. While BoNTs reach the acidic endosomal compartment in the 
presynapse, TeNT travels in various vesicles with neutral lumen inside the axon of 
motoneurons towards the spinal cord (Deinhardt and Schiavo, 2005). The molecular basis of 
the different sorting in peripheral neurons is not established so far, but could possibly be 
associated with different proteinaceous receptors of TeNT and BoNTs. Recently, 
glycosylphosphatidylinositol-(GPI)-anchored glycoproteins associated in rafts were identified 
in spinal cord cells and purified motoneurons as specific receptors for the HC-fragment of 
TeNT (Herreros et al., 2000b; Munro et al., 2001). In NGF differentiated PC12 cells the GPI-
anchored glycoprotein Thy-I was determined as binding partner of TeNT HC-fragment 
(Herreros et al., 2001). However, the relevance of gangliosides and protein receptors for the 
uptake and sorting process of TeNT are not yet deciphered in detail. 
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Tetanus neurotoxin binds via its carboxyl-terminal HC-fragment selec-
tively to neurons mediated by complex gangliosides. We investigated the
lactose and sialic acid binding pockets of four recently discovered poten-
tial binding sites employing site-directed mutagenesis. Substitution of
residues in the lactose binding pocket drastically decreased the binding
of the HC-fragment to immobilized gangliosides and to rat brain synapto-
somes as well as the inhibitory action of recombinant full length tetanus
neurotoxin on exocytosis at peripheral nerves. The conserved motif of
S1287XWY1290…G1300 assisted by N1219, D1222, and H1271 within the lac-
tose binding site comprises a typical sugar binding pocket, as also present,
for example, in cholera toxin. Replacement of the main residue of the sia-
lic acid binding site, R1226, again caused a dramatic decline in binding
affinity and neurotoxicity. Since the structural integrity of the HC-fragment
mutants was verified by circular dichroism and fluorescence spectroscopy,
these data provide the first biochemical evidence that two carbohydrate
interaction sites participate in the binding and uptake process of tetanus
neurotoxin. The simultaneous binding of one ganglioside molecule to
each of the two binding sites was demonstrated by mass spectroscopy
studies, whereas ganglioside-mediated linkage of native tetanus neuro-
toxin molecules was ruled out by size exclusion chromatography. Hence,
a subsequent displacement of one ganglioside by a glycoprotein receptor
is discussed.
q 2003 Elsevier Science Ltd. All rights reserved
Keywords: recombinant tetanus neurotoxin; HC-fragment; ganglioside
binding site; phrenic nerve toxicity assay; MALDI-TOF mass spectroscopy*Corresponding author
Introduction
Tetanus neurotoxin (TeNT) and the seven botulinum neurotoxins (BoNTs, serotypes A-G), the causative
agents of the diseases of tetanus and botulism, are produced as ,150 kDa single chain (sc) proteins in
Clostridium tetani and Clostridium botulinum. Subsequently, each toxin is cleaved by proteases into a
,100 kDa heavy chain (HC) and a ,50 kDa light chain (LC), which remain associated through a single
disulfide bridge, non-covalent interactions, and an HC-derived peptide loop wrapped around the LC.
Whereas the LCs act as zinc-dependent endopeptidases which exclusively hydrolyze certain members of
the three soluble NSF attachment protein receptor (SNARE) families, abrogating the fusion of synaptic
vesicles with the presynaptic membrane,1 – 3 the HCs are the agents of specific binding to neurons, uptake
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(NAcNeua8NAcNeua3)Galb4GlcbCer; Glc, glucose; GT1b, NAcNeua3Galb3NAcGalb4(NAcNeua8NAcNeua3)-
Galb4GlcbCer; HC, heavy chain; HC, carboxyl-terminal fragment of the HC; HCC and HCN, carboxyl and amino-
terminal domains of the HC-fragment, respectively; HN, amino-terminal fragment of the HC; LC, light chain; LT-I,
E. coli type I heat-labile enterotoxin; MALDI-TOF, matrix-assisted laser desorption ionization-time of flight; MPN,
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by receptor-mediated endocytosis, and translo-
cation of the LCs into the cytosol where the LCs
gain access to their substrates.
The HC can be subdivided into two functionally
distinct domains of ,50 kDa each. The largely
a-helical amino-terminal half (HN-domain) pro-
vides the translocation apparatus for the delivery
of the LC from the endosome into the cytosol.
This process is presumably triggered by the acidic
endosomal pH. The carboxyl-terminal domain,
referred to as the HC-fragment, mediates the highly
specific binding of clostridial neurotoxins (CNTs)
to nerve terminals at the neuromuscular junction.
While BoNTs act locally at motorneurons causing
flaccid paralysis, TeNT is transported retrogradely
within the axon to inhibitory neurons in the spinal
cord to evoke spastic paralysis.
Isolated HC-fragments retain full binding affini-
ties. It is well established that CNT HC-fragments
bind gangliosides,4 – 6 a class of glycosphingolipids
that are found particularly in membranes of
neuronal cells. Recently, the role of gangliosides
was pinpointed by inhibiting their biosynthesis
with fumonisin in primary spinal cord neurons;
this showed an insensitivity to TeNT.7 Similarly,
NAcGal-transferase knock-out mice were reported
to resist treatment with TeNT and BoNT/A, B,
and E.8 The interaction of gangliosides with CNTs
was investigated for TeNT and several serotypes
of BoNTs in extensive studies.9 These studies
revealed that the disialo carbohydrate structure as
found in GD1b is essential for the binding of
TeNT and that TeNT, BoNT/A, B, C, E, and F
showed affinities in the high nM range in in vitro
binding assays with immobilized polysialo
gangliosides, whilst binding experiments of CNTs
to neuronal tissue revealed much higher affinities
(Kd ¼ 1.2 nM). This and other discrepancies,
such as protease-sensitive binding of TeNT to
neurons,10,11 resulted in a two-receptor model
according to which polysialo gangliosides are
considered to accumulate CNTs on the plasma
membrane surface, and protein receptors to
mediate specific endocytosis.12,13 This hypothesis
was supported by the demonstration of the
binding of BoNT/A, B, and E to synaptotagmin II
in the presence of GT1b14 – 18 and the recent identifi-
cation of GPI-anchored glycoproteins in neuronal
rafts as specific receptors for the HC-fragment of
TeNT.19 – 21
The crystal structure analysis of the TeNT
HC-fragment identified two domains within HC,
an amino-terminal lectin-like jelly-roll domain
(HCN, residues 865–1110) and a carboxyl-terminal
b-trefoil domain (HCC, residues 1110–1315).
22,23
Deletion mutagenesis studies revealed that the
TeNT HCC-domain binds to gangliosides and
neuronal cells even more efficiently than the com-
plete HC-fragment,
24 whereas no binding could
be detected for the HCN-domain.
25 Moreover, the
HCC-domain constitutes the section that mediates
retrograde intra-axonal transport in chicken spinal
cord cells26 and, as demonstrated by cross-linking
experiments, interacts with the GPI-anchored glyco-
protein receptor.27
A cross-linking experiment employing [125I]azido-
GD1b and the TeNT HC-fragment led to radiolabel-
ing of H1293 in the proximity of a large cavity
within the HCC-domain.
28 This cavity was also
favored as the ganglioside binding site in com-
puter-aided docking studies with putative inhibi-
tors, in which doxorubicin was identified as a
competitive inhibitor affecting the binding of the
TeNT HC-fragment to liposome-integrated GT1b.
29
A recent co-crystallization of the TeNT HC-frag-
ment and four carbohydrate subunits of GT1b
exhibited four distinct binding sites, including the
one in the proximity of H1293, where lactose inter-
acts with the residues D1222, T1270, S1287, W1289,
Y1290, and G1300 (Figure 1).30 A separate site
comprising R1226 as the key residue coordinated
either a molecule of sialic acid or N-acetylgalactos-
amine (NAcGal; Figure 1). Two additional sites
were identified in co-crystals with galactose (Gal)
or NAcGal. However, the latter two sites are
unlikely to function as binding pockets for poly-
sialo gangliosides, due to insufficient space (Gal)
or a high flexibility of the carbon backbone
(NAcGal).
Our study aimed to clarify the molecular inter-
actions between the TeNT HC-fragment residues of
the proposed binding pockets and ganglioside
GT1b. This is a prerequisite for a rational design
of binding inhibitors to prevent the neurotoxic
action following acute intoxication. We applied
site-directed mutagenesis, to either sterically block
binding pockets with bulky side groups, or to
replace amino acid residues that appear to main-
tain ionic, H-bond, or ring stacking interactions.
We show that two ganglioside molecules associate
simultaneously with the TeNT HC-fragment and
demonstrate through binding studies and toxicity
assays that both the lactose and the sialic acid
binding pockets of the HC-fragment are vital for
the toxicity of TeNT.
Results and Discussion
Although complex gangliosides are well charac-
terized as one class of receptor molecules for
CNTs, little is known about their interaction
with the HC-fragments. Recent co-crystallization
approaches, employing the TeNT HC-fragment
and various carbohydrate elements of ganglio-
sides, exhibited four distinct binding sites in its
carboxyl-terminal b-trefoil domain.30 However, the
functionality of these sites in in vivo interactions
with gangliosides remained unclear. Furthermore,
depending on the crystallization conditions and
the resolution, X-ray structures provide only
limited insights into biochemical interactions
between molecules.
To examine the significance of the lactose and
sialic acid binding sites of the TeNT HC-fragment
for receptor binding, we generated two classes of
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mutants. Employing molecular modeling, the first
class of mutants was designed to block access to
the binding cavities. G1215 was converted to
phenylalanine in the sialic acid binding pocket,
while in the lactose-binding site, H1271 and G1300
were replaced by tryptophan or phenylalanine,
respectively. In the second approach, side groups
of amino acids, presumed to be involved in ionic,
H-bond, or ring-stacking interactions, were iso-
sterically modified, so as to suspend that par-
ticular interaction without affecting intramolecular
interactions.
Mutation of the lactose and sialic acid
interaction sites affects the binding of the
HC-fragment to isolated GT1b and synaptosomes
as well as the neurotoxicity of the full
length TeNT
To assess the influence of the various mutations
introduced into the HC-fragment on the properties
of TeNT, three different assays were performed.
(i) The ability of the full length TeNT to poison iso-
lated motorneurons was analyzed employing
mouse phrenic nerve (MPN) toxicity tests.
(ii) Binding to nerve cell membranes was studied
by means of rat brain synaptosome preparations.
(iii) The competency to interact with isolated
ganglioside was examined by ELISA.
For MPN assays, all mutants and the wild-type
TeNT were expressed in Escherichia coli under
biosafety level 2 containment as single chain (sc)
molecules fused to a carboxyl-terminal StrepTag.
Recombinant wild-type scTeNT displayed 34%
toxicity, as compared to native TeNT, while nicked
recombinant wild-type TeNT proved to be equally
potent (data not shown). Therefore, all TeNT
mutants were evaluated following trypsin acti-
vation. The measured paralytic halftimes and the
corresponding toxicities of the various mutants
are presented in Table 1.
Synaptosome binding assays were performed
employing 35S-labeled HC-fragments under physio-
logical buffer conditions, and the amount of bound
HC-fragments was quantified by phosphor ima-
ging. After two hours of incubation at 0 8C,
65(^9)% of the total wild-type HC-fragment was
associated with synaptosomal membranes. The
binding of mutated HC-fragments was specified as
the percentage of the wild-type value (Figure 2).
Binding of the radiolabeled HC-fragments proved
to be specific, since it was saturable, and the
in vitro translated protein could be displaced by
the micromolar addition of either recombinant
wild-type HC-fragment or native TeNT (data not
shown).
For interaction studies with isolated ganglio-
sides, GT1b was used, as earlier experiments on
TeNT attributed the highest binding affinities to
Figure 1. Upper panel: schematic drawing of TeNT and designation of its domains. The nicking site between LC and
HC is depicted. Regions forming the sialic acid and lactose-binding sites are highlighted by yellow and green bars,
respectively. Lower left panel: secondary structure presentation of the TeNT HC-fragment. a-Helices are presented as
dark blue cylinders, b-strands as light blue arrows, and the sialic acid and lactose bound to the HC-fragment, as identi-
fied by co-crystallization experiments, are depicted in the stick model. Lower right panel: magnified surface plot of the
HCC-domain. Amino acid residues that presumably interact with sialic acid or lactose are shown in the stick model in
yellow or green, respectively.
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this trisialo ganglioside.31,32 GT1b was immobilized
on microtiter plates and incubated with the various
HC-fragment mutants at low ionic strength. The
amount of bound mutated protein was quantified
by ELISA employing a monoclonal HC-fragment
specific antibody and expressed as the percentage
of binding of wild-type HC-fragment (Figure 3).
In the sialic acid binding pocket, the formation of
a salt bridge between the carboxyl group of sialic
acid and the guanidine group of R1226 is the most
prominent feature. This interaction can be found
in a comparable manner in both the co-crystals
with sialic acid and GT1b-b.30,33 Its importance is
highlighted by the drastic drop in toxicity to 1.4%
and the almost complete loss of binding in the
synaptosome assay and ELISA upon mutation of
R1226 to leucine or phenylalanine. Placing a bulky
phenyl ring at the opening of the binding pocket,
as implemented by TeNT-G1215F, reduced the
toxicity to 15% in the MPN assay, the binding to
18% in the synaptosome assay and approximately
to 50% in the ELISA compared to the wild-type
values. The mutation interferes with H-bonding
between D1214 and N1216 and sialic acid, and
partially shields the central R1226 residue, accord-
ing to molecular modeling analyses. These data
provide the first biochemical evidence for the
necessity of the sialic acid binding site to retain
Table 1. Biological activities of wild-type and mutated TeNT in the MPN toxicity assay
Recombinant nickeda
TeNT
Paralytic halftime t1/2
b
(minutes) at 65 nM
Paralytic halftime t1/2
b
(minutes) at 327.9 nM
Toxicity versus wild-type
TeNTc (%)
scTeNT wild-type 60.0 ^ 7.9 34.9 ^ 4.6
TeNT wild-type 43.8 ^ 4.7 100d
Sialic acid binding site mutants
TeNT G1215F 76.7 ^ 3.5 15.6 ^ 0.7
TeNT R1226F .180 98.0 ^ 15.6 1.4 ^ 0.2
TeNT R1226L .180 97.0 ^ 4.2 1.4 ^ 0.1
Lactose-binding site mutants
TeNT N1219I 171.5 ^ 16.3 1.1 ^ 0.1
TeNT N1220I 66.7 ^ 3.5 24.8 ^ 1.3
TeNT D1222L 131.0 ^ 5.7 2.6 ^ 1.3
TeNT S1287A .180 71.5 ^ 10.6 3.9 ^ 0.6
TeNT W1289G .180 138.5 ^ 13.4 0.4 ^ 0.1
TeNT W1289L .180 157.0 ^ 18.4 0.3 ^ 0.1
TeNT Y1290F 65.7 ^ 3.2 26.0 ^ 1.3
TeNT Y1290A .180 129.5 ^ 3.5 0.5 ^ 0.1
TeNT H1271A .180 139.5 ^ 14.8 0.4 ^ 0.1
TeNT H1271W .180 142.0 ^ 7.1 0.4 ^ 0.1
TeNT G1300F 100.7 ^ 4.2 6.3 ^ 0.3
TeNT H1293A 138.5 ^ 0.7 2.2 ^ 0.1
a Full length scTeNT proteins were nicked between LC and HC by trypsin immobilized on agarose beads (0.002 units/mg TeNT) for
one hour at 30 8C.
b Data are means ^ S.D. (n ¼ 3–4).
c To a five point dose-response-curve of TeNT wild-type a power function was fitted (y ¼ 154.18x20.3014, R 2 ¼ 0.999). For each
mutant the correlative concentration of wild-type was calculated and set in ratio.
d Toxicity of wild-type is set to 100%.
Figure 2. Binding of in vitro
translated 35S-labeled HC-frag-
ment mutants to rat brain
synaptosomes. Binding experi-
ments were performed in
physiological buffer for two
hours at 0 8C. Washed pellet
fractions were subjected to
SDS-PAGE and the amount of
bound [35S]HC-fragment mutants
was quantified by phosphor
imaging and depicted as per-
centage of wild-type binding.
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the neurotoxicity of TeNT. Interestingly, compari-
son of the sialic acid binding site of TeNT with the
active sites of viral neuraminidases revealed simi-
lar structural features.34,35
Mutations designed to sterically block access to
the lactose-binding pocket, i.e. replacement of the
H1271 imidazole side group by a bulky indole,
and the addition of a benzyl function in place of
the G1300 hydrogen, resulted in a dramatic loss in
toxicity. 0.4% and 6.3% residual toxicity were
measured for H1271W and G1300F, respectively.
Furthermore, those mutations also severely inter-
fered with binding to synaptosomes and ganglio-
sides, resulting in 2% and 12% or 7% and 38%
residual binding, respectively.
The mutant TeNT-H1271A displayed barely
detectable toxicity. Consistently, this elimination of
the imidazole ring caused a drastic loss in the bind-
ing to synaptosomes and diminished the affinity
for GT1b to less then 20%. These results indicate
important interactions between sugar hydroxyl
groups of GT1b and the imidazole ring, although
no interactions between H1271 and lactose could
be observed in the co-crystal formed with the
HC-fragment.
30 Our findings support the data of
the GT1b-b/HC-fragment co-crystallization accord-
ing to which the freely rotatable imidazole ring of
H1271 forms H-bonds between ND1 and O-4 and
O-6 of Gal4.33 Hence, it does not expose its p-elec-
tron system towards the pocket as does W1289,
due to a coordination by the backbone carbonyl
oxygen of N1272.
Mutations of D1222 to leucine and of the neigh-
boring S1287 to alanine strongly decreased the
biological activity at the MPN as well as binding
to synaptosomes and immobilized GT1b. This
agrees with the formation of important H-bonds,
as predicted by the lactose co-crystal. In contrast,
S1287 unexpectedly showed no interaction with
GT1b-b in the HC-fragment co-crystal.
33 Another
important discrepancy turns up in the polar inter-
action between N1220 and O-3 of the Glc portion,
and in the passive role of the adjacent N1219 as
found in the lactose co-crystal. We determined
that the mutation of N1220 to isoleucine hardly
influenced the TeNT binding characteristics and
only moderately affected toxicity, whereas the
mutation N1219I led to a nearly inactive neuro-
toxin due to its low affinity to gangliosides. This
result demonstrates the flexibility of the loop,
including residues F1218 to D1222, which allows
N1220 to move out of the binding area and N1219
to shift towards the carbohydrate binding site and
corroborates the side-chain arrangement observed
in the GT1b-b/HC-fragment co-crystal.
33
As signified by the discrepancies between our
biochemical and the structural data described
above, these analyses reveal that lactose as a
mimicking agent for the carbohydrate structure of
gangliosides is limited. In addition, the up to 890
times lower concentration of GT1b-b used for
co-crystallization33 and the lack of competition
between wild-type HC-fragment and lactose,
NAcGal, or sialic acid in the range of 0.3 to
300 mM on binding to rat brain synaptosomes
(data not shown) substantiate this conclusion.
The conservative exchange of Y1290 for phenyl-
alanine yielded a TeNT with 25% toxicity and
retained almost wild-type binding characteristics,
whereas removal of the phenyl ring, yielding
A1290, or its replacement by serine, displayed
hardly detectable toxicity and only residual bind-
ing below 20% in both binding assays. These
results suggest an inferior role of the hydroxyl
group in ligand interaction, but emphasize the
importance of the phenyl ring for the functioning
of this site (see below).
The substitution of W1289, situated above Y1290,
by aliphatic amino acid residues (leucine, valine,
glycine) generated nearly non-toxic molecules and
caused the most severe reduction in binding
among all mutations at the lactose-binding pocket.
Thus, W1289 plays a dominant role in ganglioside
interaction at the lactose-binding site. Supposedly,
its indole group, defining one wall of the binding
cavity, allows a sugar ring to stack parallel with
Figure 3. Binding of TeNT
HC-fragment mutants to 1 mg
ganglioside GT1b immobilized
on microtiter plates. The
amount of bound HC-fragments
was determined, using a mono-
clonal TeNT HC-fragment
specific antibody, and illus-
trated as percentage of wild-
type binding.
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the aromatic ring system. Our data approve this
hydrophobic ring stacking interaction that was
postulated due to a tryptophan fluorescence
quench upon ganglioside binding to the corre-
sponding site of BoNT/A,36,37 a theoretical docking
study,29 and two co-crystallization approaches.30,33
Earlier cross-linking experiments employing
GD1b implicated H1293 in ganglioside inter-
action.28 Contrariwise, its mutation to serine or ala-
nine did not affect the binding to motorneurons.38
In our hands, these exchanges resulted in a signifi-
cant reduction in binding to neuronal cell mem-
branes to 18% and 12%, respectively. In line with
this result, toxicity of TeNT-H1293A was drastically
diminished. However, a direct involvement of
H1293 in carbohydrate binding can largely be
ruled out, since its imidazole ring is not a part of
the binding cavity lining but is shielded by W1289
(see Figure 1). The impairment in binding affinity
by removal of the imidazole group can rather be
explained by the displacement of W1289, whose
side group is positioned by the parallel oriented
H1293 imidazole, thus by a lack of coordination
via ring stacking interactions.
Comparison of the lactose-binding site with
ganglioside binding domains of other bacterial
protein toxins shows that the AB5 toxins cholera
toxin (CT) and E. coli type I heat-labile enterotoxin
(LT-I) interact in a bidental mode with the
monosialo ganglioside GM1.39,40 Contrary to the
salt bridge between the carboxyl group of NAcNeu
and R1226 in TeNT, the sialic acid branch of GM1
binds via its N-acetyl group to Y12 of CT (Figure
4(B)). The terminal Gal, however, interacts with
residues analogous to amino acid residues in the
lactose-binding site of the TeNT HCC-domain that
constitute a similarly shaped second binding cavity
(Figure 4). Further similarities can be found in the
type-II ribosome-inactivating proteins (RIPs) ricin
and ebulin, disulfide-linked heterodimers com-
posed of an enzymatic A chain and a lectin B
chain, which specifically interacts with terminal
Gal in glycolipids and glycoproteins. The B chains
fold as two b-trefoil domains, like that of the
TeNT HCC-domain, and their crystal structures
revealed two binding pockets for Gal.41,42
Altogether, single mutations within the investi-
gated carbohydrate binding sites generate TeNT
molecules nearly lacking any binding affinity.
Thus, the data clearly indicate that both the lactose
and the sialic acid binding site are essential for
receptor interaction and the toxicity of TeNT.
This conclusion relies on analyses in three different
assay systems that provided consistent results. The
effects of the individual mutations measured for
GT1b interaction substantially agreed with those
for synaptosome binding. The impacts on binding,
however, proved to be in general less pronounced
compared to the results of the MPN toxicity assay,
but the proportion of the effects among the indi-
vidual mutations was largely maintained in all
three assay systems. The stronger effects, observed
in the MPN toxicity test, might be ascribed to the
lower availability of receptor molecules.
Spectroscopic structure analyses of mutated
HC-fragments
To exclude the possibility that the individual
mutations had affected structural elements of the
HC-fragment, far-UV CD spectra were recorded.
The spectra of all mutants showed a single mini-
mum at 208 nm, typical of proteins rich in b-sheet
conformation and a low a-helical content (data
not shown). The spectra of all HC-fragment
mutants, except for Y1290A, were essentially
indistinguishable from the wild-type trace and
secondary structure calculations, employing the
methods of CONTIN, SELCON3, and CDSSTR,43
predicted 3(^1)% a-helix, 37(^3)% b-sheet,
22(^2)% turns, and 38(^3)% random coil for
wild-type TeNT HC-fragment and the various
mutants. These values are in line with the crystal
structure of the TeNT HC-fragment (5% a-helix,
Figure 4. Co-crystal structures of TeNT and CT with gangliosides. Similar interactions are present between the charac-
teristic tryptophan residues and the terminal galactoses of GT1b-b within the TeNT lactose binding site (A; modified
from 1FV2.pdb33), and GM1 and the CT binding unit (B; modified from 2CHB.pdb39), respectively. Carbon atoms of pro-
tein residues are colored in green, of ganglioside sugars in yellow and of sialic acids in orange. The bidental binding
mode of GM1 to CT additionally employs the sialic acid branch, which is sterically impossible in the case of TeNT.
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35% b-sheet, 60% turns/random coil).22 Interest-
ingly, the b-sheet content of the Y1290A mutant
was reduced by 6% while the a-helical content
was doubled to 7% (see below).
To inspect the conformation of the mutated
HC-fragments in more detail, temperature-induced
denaturing measurements were conducted.
Changes in the molar ellipticity at 220 nm were
recorded as a function of temperature. The traces
are well described by steeply sigmoidal curves,
which provide the melting temperatures (tm) at
their inflection points. The traces obtained for the
wild-type HC-fragment and the double mutant
G1215F/R1226F were virtually identical, yielding
tm-values of 58.4 8C, and 57.6 8C, respectively.
These were within the inaccuracy of about 0.8 8C
for measurements of the same sample (Figure
5(A)). HC-R1226L exhibited a slightly higher
tm-value of 60.3 8C, probably due to novel hydro-
phobic interactions between L1226 and P1212 as
revealed by molecular modeling analysis. Spectra
of the mutants of the lactose-binding site displayed
an array of curves with tm-values ranging from
56.6 8C to 59.4 8C, thus differing by less than 1.5 8C
from the wild-type value (Figure 5(B)). Only the
HC-fragment mutant Y1290A showed a signifi-
cantly lower melting temperature of 53.7 8C,
matching the already observed overall change in
secondary structure content. The lower thermo-
stability of mutant Y1290A, compared to mutant
Y1290F, can apparently be ascribed to the missing
phenyl ring, which presumably causes an expan-
sion of the 310-helix H5 (S1287 to H1293)
22 invol-
ving residues L1294 and K1295, as analyzed by
molecular modeling. One consequence is a shift of
the H1293 imidazole ring towards W1289, which
culminates in the displacement of W1289 from the
lactose-binding cavity, and consequently impairs
the integrity of the local structure. Thus, the low
binding affinity observed, when the phenyl ring in
mutant Y1290A was removed, appears to be indir-
ect. Therefore, we conclude in opposition to the
earlier report of Sutton et al.44 that the relocation of
amino acid residues directly involved in ganglio-
side binding, for example W1289, causes the phe-
notype of the mutants Y1290A and Y1290S.
As a further approach to assess the structural
integrity of the lactose-binding site upon mutation
of the sialic acid binding site, fluorescence spectra
for wild-type HC-fragment and HC-G1215F/
R1226F alone, and in the presence of GT1b were
recorded. It was previously shown for BoNT/A
that the tryptophan fluorescence signal excited by
light of 295 nm wavelength is quenched in the pre-
sence of GT1b in low ionic strength buffer.36 On the
basis of our above presented results, according to
which W1289 constitutes a central residue in the
lactose-binding site, and the fact that this strictly
conserved residue is located in analogous positions
in TeNT, BoNT/A, and BoNT/B, this tryptophan
likely accounts for fluorescence quenching. As
presented in Figure 6, GT1b quenched the trypto-
phan fluorescence of HC-G1215F/R1226F to the
same extent as does wild-type HC-fragment. As
expected, no quench was observed in the case of
HC-N1219I/D1222L (data not shown). Thus, these
data confirm results of the thermal denaturing
experiments and demonstrate that mutation of the
sialic acid binding site left the lactose-binding site
unharmed.
Sequence and structural homology of the
binding sites throughout CNTs
In a sequence and structural alignment study
within the less conserved HCC-domains of TeNT
and BoNT/A, B, E, F, and G (23% sequence
Figure 5. Temperature-induced denaturing of the
wild-type TeNT HC-fragment and various mutants. The
CD signal at 220 nm was monitored at protein concen-
trations of 75 mg/ml and a temperature increase of
0.9 8C/minute from 25 8C to 80 8C. Analysis of mutants
of the sialic acid binding site (A): HC-wild-type ( £ ),
R1226L (B), G1215F/R1226F (A) or the lactose-binding
site (B): HC-wild-type ( £ ), N1220I (þ), N1219I/D1222L
(S), S1287A (–), W1289G (O), W1289L (K), Y1290F (X),
Y1290A (W), H1271A (B), H1271W/G1300F (A), and
H1293A ( p ).
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similarity on average), 12 structurally conserved
regions, each of five residues, were identified as
b-trefoil forming segments; 44 of these 60 amino
acid residues are highly conserved.45 This sequence
homology was confirmed by the similar secondary
structure found in the crystals of BoNT/A and
B.46,47 Moreover, employing the coordinates of
BoNT/A, BoNT/B, and TeNT HC-fragment in
electrostatic surface plots, in both BoNT serotypes
a cavity of similar size (,9 A˚ £ , 9 A˚) in a
position analogous to the lactose-binding pocket
of TeNT is formed by a homologous set of amino
acid residues, i.e. G, H, S, W, Y. The “SXWY…G”-
motif is strictly conserved throughout TeNT and
BoNT/A, B, E, F, and G, while in BoNT/C serine
and glycine switch their positions. Serotype D is
exceptional in this respect, because only the central
tryptophan of this motif is maintained. Altogether,
the conserved lactose-binding pocket in the
HCC-domains is presumably essential for ganglio-
side binding of all serotypes. This hypothesis is
supported by the co-crystallization of BoNT/B
with sialyllactose, where this trisaccharide
occupies the analogous lactose binding site.47
Although here the carbohydrate binding mode
seems to differ to some extent, the lactose-binding
site may constitute a target for the development
of an inhibitor directed against all CNTs.
Knowledge of the precise carbohydrate–protein
interactions is the prerequisite for a rational
inhibitor design.
A search for an equivalent of the TeNT sialic acid
binding site in electrostatic surface plots of BoNT/
A and BoNT/B HC-fragment did not succeed. It
remains to be shown whether BoNTs possess only
one ganglioside interaction site or structurally
different sites adopted that function.
TeNT HC-fragment binds two GT1b molecules
The results of the mutational analysis advised
that both, the lactose and the sialic acid binding
pocket of TeNT are directly involved in ganglioside
binding, as also supported by co-crystals of the
TeNT HC-fragment and a synthetic GT1b-b sugar
portion.33 Although a bidental binding mode, as
present in CT, can largely be ruled out due to
the large distance between both binding sites
(W1289$ R1226: 23 A˚ on the surface; Figure 4),
mass spectroscopy analyses were performed to
definitely distinguish between binding of two
ganglioside molecules and simultaneous binding
of one molecule to both sites. Masses of HC-frag-
ment/ganglioside complexes were determined
employing the MALDI-TOF principle. The
measurements of the wild-type HC-fragment,
HC-G1215F/R1226F, and HC-N1219I/D1222L
(Figure 7(A), (C) and (E)) provided m/z values
closely matching their theoretical masses and were
thus used for internal calibration. Analyses
following pre-incubation with 20-fold molar excess
of GT1b for 30 minutes at 37 8C generated extra
peaks at m/z 55,863.9 Da, 55,876.6 Da, and
55,808.4 Da (decorated with p in Figure 7(B), (D)
and (F)), representing a mass increase of 2180 Da,
2110 Da, and 2120 Da, respectively. These gains in
m/z are in close accord with the molecular mass
of GT1b of 2180 Da, indicating binding of one
GT1b molecule. Furthermore, an additional peak
at m/z 57,794.1 Da was observed for the wild-type
HC-fragment/GT1b mixture (highlighted by p p
in Figure 7(B)). This mass shift by ,4100 Da
demonstrates the simultaneous binding of two
molecules of GT1b to the two carbohydrate
binding sites of TeNT.
GT1b does not induce oligomerization of
native TeNT
Encouraged by results of the mass spectroscopy
analyses and the recent finding that addition of a
synthetic GT1-b sugar portion to the mother liquor
of the TeNT HC-fragment seems to link two bind-
ing domains within different unit cells,33 we
Figure 6. Tryptophan fluor-
escence quenching in the
lactose-binding site of TeNT
HC-fragment upon GT1b bind-
ing. Spectra were recorded in
the absence or the presence of
tenfold molar excess of GT1b:
HC-wild-type ( £ ), HC-wild-
type þ GT1b (þ), HC-G1215F/
R1226F (A), HC-G1215F/
R1226F þ GT1b (B).
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investigated the putative linking in solution.
Native TeNT (100 mg; 1.1 mM) was incubated in
the presence of various concentrations of complete
GT1b (1.1 mM, 2.2 mM, 5.5 mM, 11.1 mM). Subse-
quent size exclusion chromatography (SEC)
revealed multimer formation only when exceeding
the critical micellar concentration (CMC) of GT1b
(10(^5) mM;48 data not shown). The observation
of high molecular mass complexes can thus be
ascribed to the binding of TeNT to developing
GT1b micelles. This is in line with results of earlier
ultracentrifugation experiments by Lazarovici
et al.49 Therefore, linking of TeNT molecules via
complex gangliosides does apparently not occur
in low ionic strength solutions.
Role of the dual ganglioside binding capacity
of TeNT
A cooperation of gangliosides with a protein-
aceous receptor in TeNT binding was postulated
to explain findings of previous research.12 As
BoNTs conceivably do not exhibit a carbohydrate
binding site equivalent to the sialic acid binding
site (see above), it is tempting to speculate that
this site might subsequently interact with a protein
receptor. Recently, a glycosylated, GPI-anchored
protein, clustered within lipid rafts, was identified
as a supplementary cell surface receptor for
TeNT.20,21 In this scenario, in a first step abundant
gangliosides on the neuronal cell surface would
Figure 7. Binding of GT1b to wild-type and mutated HC-fragments assessed by MALDI-TOF mass spectroscopy.
Mass spectra of (A) HC-wild-type, (C) HC-G1215F/R1226F, and (E) HC-N1219I/D1222L. Mass spectra of (B) HC-wild-
type, (D) HC-G1215F/R1226F, and (F) HC-N1219I/D1222L after incubation with 20-fold molar excess of GT1b. Insets
show the range of 55,000 to 59,000 (m/z) with different scaling of the y-axis. Asterisks mark ganglioside/HC–fragment
complexes. Extra peaks in the range of 57,925 to 58,360 (m/z) represent unidentified impurities of the HC-fragment
preparations.
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attract TeNT, employing both of the two carbo-
hydrate binding pockets. The association of
gangliosides within lipid rafts,40 and the co-exist-
ence of the glycoprotein receptor would then
allow a displacement of the bound ganglioside in
the sialic acid binding site by the carbohydrate por-
tion of this GPI-anchored glycoprotein. This
exchange may be driven by a higher affinity of
TeNT for the carbohydrates of the glycoprotein.
Protein–protein interactions may contribute as
well. Furthermore, the association of TeNT to raft
components would include lipid microdomains
that are specialized in the internalization of pro-
teins and pathogens,50,51 allowing endocytosis and
subsequent retrograde intra-axonal transport, a
special feature of TeNT amongst the CNTs. There-
fore, the sialic acid binding pocket may be a prere-
quisite for the different sorting of TeNT versus
BoNTs proceeding in peripheral neurons upon
endocytosis. Further studies are required to clarify
the formation of this glycoprotein–TeNT complex.
Materials and Methods
Molecular modeling
Molecular modeling was done using an Octane work-
station (Silicon Graphics, Inc.) and the Insight II 2000
software (Molecular Simulations, Inc.).
Plasmid constructions
The gene portion encoding the HC-fragment of TeNT
was fused to an oligonucleotide coding for the StrepTag
and inserted into pQE3 (Qiagen) yielding the expression
plasmid pAR11. Mutations in the HC-fragment were
generated by PCR, using pAR11 as template DNA and
suitable primers. The PCR products were digested
and inserted into the correspondingly cleaved pAR11
and the transcription vector pSP72 (Promega). Nucleo-
tide sequences of all mutants were verified by DNA
sequencing. The plasmid encoding full length wild-type
TeNT with carboxyl-terminal StrepTag (pAR1) was con-
structed using pSP64tet97/7, pEJ6/3,52 and pAR11.
Fragments of the mutated pAR11 plasmid were trans-
ferred into pAR1, to yield the corresponding full length
TeNT mutants.
Purification of recombinant proteins
Wild-type and mutated recombinant HC-fragments
and full length TeNT, fused to a carboxyl-terminal Strep-
Tag, were produced utilizing the E. coli strain M15pREP4
(Qiagen) during ten hours of incubation at room tem-
perature, and were purified on StrepTactin-Sepharose
beads (IBA GmbH) following to the manufacturer’s
instructions. The carboxyl-terminal StrepTag was not
removed, as tagged HC-fragments and corresponding
HC-fragments with authentic carboxyl termini exhibited
indistinguishable properties in our binding assays. Frac-
tions containing the desired proteins were pooled, frozen
in liquid nitrogen, and kept at 270 8C. HC-fragments
designated for CD analyses were further purified to a
purity of .96%, by SEC (Superdex 200 column, A¨kta
purifier, Amersham Pharmacia Biotech) in Lubrol buffer
(20 mM Tris–HCl buffer (pH 7.2), containing 100 mM
NaCl, 0.01% Lubrol (v/v)).
Mouse phrenic nerve toxicity assay
The MPN toxicity assay was set up as described by
Habermann et al.53 Electrical stimulation of the phrenic
nerve was continuously performed at a frequency of
1 Hz. Isometric contractions were transformed with a
force transducer and recorded with the VitroDat Online
software (FMI GmbH). The time required to decrease
the amplitude to 50% of the starting value (paralytic half-
time) was measured. Full length scTeNT or its mutants
were nicked between LC and HC, applying trypsin
immobilized on agarose beads (Sigma-Aldrich, 0.002 U/
mg TeNT) during one hour of incubation at 30 8C. Proteo-
lytic activation proved to be complete and no degra-
dation of the resulting LC and HC was detectable by
Coomassie blue staining for any of the mutants (data
not shown). The nicked wild-type TeNT was applied in
triplicate at final concentrations of 0.66, 1.97, 6.65, 19.67,
and 65.57 nM, to plot a dose-response curve to which
the power function y ¼ 154.18x20.3014 (R 2 ¼ 0.999) can be
ascribed. TeNT mutants were tested in triplicate at either
65.57 nM or 327.87 nM final concentrations. The resulting
paralytic halftimes were converted to the corresponding
concentrations of wild-type TeNT, using the equation
mentioned above. The toxicities were finally expressed
as a percentage of wild-type activity.
The catalytic activity of the LC of all mutants was
validated in cleavage assays employing 35S-labeled rat
synaptobrevin 2 and nicked TeNT at a final concentration
of 0.3 mM (data not shown).
In vitro transcription and translation
HC-fragments were synthesized in vitro from the line-
arized pSP72 derivatives, using the reticulocyte lysate
system (Promega) in the presence of L-[35S]methionine
(555 KBq, .37 TBq/mmol; Amersham Pharmacia Bio-
tech), in a total volume of 25 ml.
Binding assay using rat brain synaptosomes
Synaptosomes were obtained following the protocol
described by Jones & Matus.54 Brains were dissected
from 150 g Wistar rats and the cerebellum, pons and
medulla were discarded. The remainder of the brains
was homogenized in 10 ml of 0.32 M sucrose, adjusted
to pH 7.3 with 5 mM Hepes–NaOH, and the homo-
genate was centrifuged at 4 8C for ten minutes at 800g
followed by centrifugation of the supernatant fraction at
12,000g for 15 minutes. The resultant pellet was washed
once and resuspended in 2 ml of sucrose buffer. This sus-
pension was layered on top of a discontinuous gradient
consisting of 10%, 15%, and 23% Percoll and centrifuged
for seven minutes at 33,000g. Functional synaptosomes
were recovered from the 15–23% Percoll interface, care-
fully diluted in physiological buffer (140 mM NaCl,
5 mM KCl, 1 mM MgCl2, 20 mM Hepes, 5 mM NaHCO3,
1.2 mM Na2HPO4, 10 mM glucose, 0.5% (w/v) BSA, pH
7.4), and centrifuged at 12,000g for 15 minutes. The pellet
fraction was resuspended in physiological buffer, with
the final synaptosomal protein adjusted to a concen-
tration of 10 mg/ml.
Binding assays were performed in triplicate, in a
total volume of 100 ml of physiological buffer for two
hours at 0 8C, containing a 5 ml aliquot of the translated
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HC-fragment (reaching a final concentration of ,3 pM)
and 30 ml of the synaptosome suspension. For com-
petition assays various amounts of the recombinant
wild-type HC-fragment, native TeNT, sialic acid, NAcGal,
or lactose were added as well. Control samples lacking
synaptosomes were treated equally. After incubation,
the synaptosomes were collected by centrifugation
(5000g; five minutes) and unbound material in the super-
natant fraction was discarded. The pellet fractions were
washed twice each with 50 ml of physiological buffer
and boiled in SDS sample buffer. The samples were
analyzed by SDS-PAGE, together with a 5 ml aliquot of
translated HC-fragment to verify efficiency of translation.
Bound 35S-radiolabeled HC-fragments were visualized
using a BAS-1500 phosphor imager (Fuji Photo Film),
and quantified applying the Tina 2.09f software (Raytest
Isotopenmeßgera¨te GmbH). Amounts of bound HC-frag-
ments were calculated after subtraction of the control
value as a percentage of the total HC-fragment protein
in the assay, and finally compared with the binding
efficiency of the wild-type HC-fragment.
Binding to ganglioside GT1b
Ganglioside GT1b (Sigma-Aldrich) was dissolved to
10 mg/ml in methanol and applied to high-affinity
96-well polystyrene microtiter plates (Costar) (100 ml/
well). The solvent was evaporated at room temperature
and the wells were washed three times with binding
buffer (10 mM Tris–HCl, 10 mM Na2HPO4, 0.5% BSA,
pH 7.2). Binding assays were performed in binding buf-
fer (100 ml/well) containing 250 ng HC-fragment for two
hours at room temperature. Unbound protein was
removed by three washing steps, each one with 250 ml
of PBS/Tween buffer (140 mM NaCl, 7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4, 0.05% (v/v) Tween 20, pH
7.2). After blocking unspecific binding sites using 3%
(w/v) milk powder in PBS buffer (two hours at room
temperature), bound HC-fragments were detected by
sequential incubations, each of two hours at room tem-
perature, with a monoclonal mouse anti-TeNT HC-frag-
ment antibody (ascites liquid, 1:100 diluted in binding
buffer) and peroxidase-conjugated goat anti-mouse anti-
body (Jackson Immuno Research Laboratories, Inc.).
1,2-diaminobenzene (4 mM dissolved in 2% H2O2,
32 mM Na-citrate, 68 mM Na2HPO4, pH 5.5) was used
as the substrate, and the extinction at 490 nm was
scanned with a SpectraCount microplate photometer
(Packard).
CD spectroscopy
CD data were collected with a Dichrograph III (Jobin-
Yvon) spectropolarimeter equipped with a computer-
controlled temperature cuvette holder. Far-UV data in
the range of 200 to 250 nm were obtained with a 0.1 mm
path length cuvette, containing 0.5–1.0 mg/ml protein
in Lubrol buffer. CD spectra were recorded at 21 8C, at a
speed of 6 nm/minute and with a response time of
two seconds. Temperature-induced denaturation was
performed in the same buffer at a protein concentration
of 75 mg/ml, by monitoring the CD signal at 220 nm in
a 4 mm path length cuvette. The temperature increase of
0.9 8C/minute from 25 8C to 80 8C was measured directly
in the protein solution with a thermistor.
Tryptophan fluorescence quench measurements
Wild-type TeNT HC-fragment, the double mutants
HC-G1215F/R1226F, and HC-N1219I/D1222L and a
combined quadruple mutant thereof were purified in
binding buffer (minus BSA) by SEC. 3.6 mg of each
HC-fragment (1.1 mM) was incubated with 22 mM GT1b
in binding buffer (minus BSA) for 30 minutes at 37 8C.
Subsequently, tryptophan fluorescence signals were
collected with a RF-2001PC spectrofluorimeter
(Shimadzu) equipped with a computer-controlled
temperature cuvette holder at 37 8C with an excitation
wavelength of 295 nm. The fluorescence spectra were
recorded in the range of 280 to 420 nm using a 0.3 mm
path length cuvette.
Mass determination of TeNT HC-fragment/
GT1b complexes
Wild-type TeNT HC-fragment and the double mutants
HC-G1215F/R1226F and HC-N1219I/D1222L were puri-
fied in binding buffer (minus BSA) by SEC. 1.8 mg of
each HC-fragment (1.6 mM) was incubated with or with-
out 32 mM GT1b in binding buffer (minus BSA) for 30
minutes at 37 8C. Aliquots (5 ml) of each mixture were
mixed in a 1:1 ratio with either of the matrices of a
saturated sinapinic acid solution or EAM-1 (Ciphergen
Biosystems) in 50% acetonitrile-water containing 0.5%
trifluoroacetic acid. Twice, 2 ml of each mixture were
dropped on an eight-spot gold surface chip and air-
dried. Data were collected by a surface enhanced laser
desorption/ionization time of flight mass spectrometer
(SELDI-TOF MS) PBS II (Ciphergen Biosystems) and
analyzed with the Ciphergen ProteinChip software 3.0.1.
HPLC analysis of TeNT/GT1b complexes
Native TeNT was purified in binding buffer (minus
BSA) by SEC (Superdex 200 column, detection 280 nm,
A¨kta purifier), and the fractions at a retention volume
Ve of 11.8 ml, containing TeNT monomer, were collected.
100 mg of native TeNT monomer and GT1b were incu-
bated in various molar ratios (1:0, 1:1, 1:2, 1:5, and 1:10)
for one hour at 0 8C in binding buffer (minus BSA, plus
12% methanol). Again, they were subjected to SEC to
check formation of TeNT/GT1b-complexes.
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Summary
Tetanus and botulinum neurotoxins selectively invade
neurons following binding to complex gangliosides.
Recent biochemical experiments demonstrate that
two ganglioside binding sites within the tetanus neu-
rotoxin H
 
C
 
-fragment, originally identified in crystallo-
graphic studies to bind lactose or sialic acid, are
required for productive binding to target cells. Here,
we determine by mass spectroscopy studies that the
H
 
C
 
-fragment of botulinum neurotoxins A and B bind
only one molecule of ganglioside GT1b. Mutations
made in the presumed ganglioside binding site of
botulinum neurotoxin A and B abolished the forma-
tion of these H
 
C
 
-fragment/ganglioside complexes,
and drastically diminished binding to neuronal
membranes and isolated GT1b. Furthermore, corre-
spondingly mutated full-length neurotoxins exhibit
significantly reduced neurotoxicity, thus identifying a
single ganglioside binding site within the carboxyl-
terminal half of the H
 
C
 
-fragment of botulinum neuro-
toxins A and B. These binding cavities are defined by
the conserved peptide motif H…SXWY…G. The roles
of tyrosine and histidine in botulinum neurotoxins A
and B in ganglioside binding differ from those in the
analogous tetanus neurotoxin lactose site. Hence,
these findings provide valuable information for the
rational design of potent botulinum neurotoxin bind-
ing inhibitors.
Introduction
 
Seven botulinum neurotoxins (BoNTs, serotypes A–G),
produced by various strains of 
 
Clostridium botulinum
 
, 
 
C.
barati
 
 and 
 
C. butyricum
 
, are the causative agents of the
disease botulism. These bacterial protein toxins and the
closely related tetanus neurotoxin (TeNT) synthesized by
 
C. tetani
 
 are produced as 
 
~
 
150 kDa single chain (sc)
proteins and subsequently cleaved by proteases into a
 
~
 
100 kDa heavy chain (HC) and a 
 
~
 
50 kDa light chain
(LC), which remain associated through a single disulphide
bridge and non-covalent interactions. The recent elucida-
tion of the crystal structures of BoNT/A and B (Lacy 
 
et al
 
.,
1998; Swaminathan and Eswaramoorthy, 2000) illustrates
that all clostridial neurotoxins (CNTs) are composed of
three functionally independent domains that perform indi-
vidual tasks in the multistep intoxication process.
Intoxication at the neuromuscular junction starts with
specific binding to peripheral nerve endings. It is well
established that this adherence involves gangliosides (van
Heyningen and Miller, 1961; Simpson and Rapport, 1971;
van Heyningen, 1974; Williamson 
 
et al
 
., 1999; Yowler
 
et al
 
., 2002), a class of complex glycosphingolipids that
are found particularly in membranes of neuronal cells, and
the carboxyl-terminal half of the HC, the H
 
C
 
-fragment (H
 
C
 
).
This H
 
C
 
-fragment is composed of an amino-terminal (H
 
CN
 
)
lectin-like jelly roll domain and a carboxyl-terminal (H
 
CC
 
)
 
b
 
-trefoil domain (Umland 
 
et al
 
., 1997; Lacy 
 
et al
 
., 1998;
Knapp 
 
et al
 
., 1998; Swaminathan and Eswaramoorthy,
2000). As an isolated fragment, H
 
CC
 
 retains full binding
affinity (Halpern and Loftus, 1993), whereas the H
 
CN
 
-
domain has no known function. Following cell attachment,
internalization via receptor-mediated endocytosis brings
the neurotoxins into the endosomal compartment. Here,
the acidic environment allows the structural rearrange-
ment and concomitant insertion of the largely 
 
a
 
-helical
amino-terminal half of the HC, the H
 
N
 
-domain, into the
membrane. At the same time the LC is partially unfolded
(Koriazova and Montal, 2003). Upon reduction of the dis-
ulphide bond, the LC functions as a zinc dependent
endopeptidase in the cytosol. CNT LCs hydrolyse specific
SNARE (soluble NSF attachment protein receptor) pro-
teins, thereby abrogating the fusion of synaptic vesicles
with the presynaptic membrane (reviewed in Niemann
 
et al
 
., 1994; Bigalke and Shoer, 2000; Schiavo 
 
et al
 
.,
2000).
Intoxication by BoNTs and TeNT produces two truly
opposite symptoms, flaccid paralysis caused by BoNTs
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and spastic paralysis evoked by TeNT. BoNTs act at their
site of entry in synapses at the neuromuscular junction,
whereas TeNT undertakes a journey within the axon of
motorneurons by vesicular transport toward the spinal
cord. Here, it is discharged into the synaptic cleft, binds
to an inhibitory interneuron, undergoes endocytosis and
translocation to the cytosol where the LC acts to finally
inhibit neurotransmitter release. The molecular basis for
that different sorting in peripheral neurons is so far not
established.
Possibly, CNTs associate with different proteinaceous
co-receptors. Indeed, a two-receptor model was postu-
lated to account for greatly differing affinities observed for
CNTs binding 
 
in vitro
 
 compared with binding 
 
in vivo
 
 as
well as for the identified protease-sensitive binding of
TeNT to neurons (Lazarovici and Yavin, 1986; Pierce
 
et al
 
., 1986). Binding to ganglioside occurs in the high nM
range, whereas binding at neuronal tissue is more avid
(K
 
d
 
 = 1.2 nM). In the two-receptor model, polysialogangli-
osides are considered to accumulate CNTs on the plasma
membrane surface, and protein receptors are supposed
to mediate specific endocytosis (Montecucco, 1986;
Niemann, 1991). Later, synaptotagmin II was shown
to be involved in the binding of BoNT/B (Nishiki 
 
et al
 
.,
1994, 1996a, b; Kozaki 
 
et al
 
., 1998; Dong 
 
et al
 
., 2003),
and glycosylphosphatidylinositol-(GPI)-anchored glyco-
proteins in neuronal rafts were recently identified as spe-
cific receptors for the H
 
C
 
-fragment of TeNT (Herreros
 
et al
 
., 2000a, 2001; Munro 
 
et al
 
., 2001). Their binding site,
however, and the relevance of gangliosides and protein
receptors for the uptake and sorting process, beyond the
fact that the H
 
CC
 
-domain of TeNT interacts with a GPI-
anchored glycoprotein (Herreros 
 
et al
 
., 2000b) and medi-
ates retrograde intra-axonal transport in chicken spinal
cord cells (Rummel 
 
et al
 
., 2001), are not ultimately deci-
phered. Also, it is unclear at present, whether the recently
discovered involvement of two ganglioside binding sites in
the intoxication process of TeNT is a peculiarity of this
neurotoxin and whether it relates to its retrograde intra-
axonal transport.
Both binding sites on TeNT, originally identified by their
ability to bind lactose or sialic acid, have recently been
localized by co-crystallization approaches and biochemi-
cal experiments employing TeNT mutants (Emsley 
 
et al
 
.,
2000; Fotinou 
 
et al
 
., 2001; Rummel 
 
et al
 
., 2003). The lac-
tose binding site is characterized by the presence of the
peptide motif H…SXWY…G. This motif is conserved
among the majority of BoNTs (Fig. 1), and crystallo-
graphic data available on BoNT/A and B (Lacy 
 
et al
 
.,
1998; Swaminathan and Eswaramoorthy, 2000) revealed
a structural resemblance of these segments with the lac-
tose binding pocket of TeNT (Fig. 2). In addition, results
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Fig. 1.
 
 Amino acid sequence alignment of TeNT 
(T) and BoNT (A–G) H
 
CC
 
-fragments. Identical 
amino acids are presented in white letters on 
black background. Amino acids conserved in 
the majority of sequences are shaded grey, and 
those known to build the lactose and sialyllac-
tose binding pockets of TeNT and BoNT/B, 
respectively, as well as the proposed equivalent 
amino acids in the structure of BoNT/A are 
boxed. Positions of amino acids of BoNT/A or 
B selected for mutational analyses are high-
lighted by asterisks below the sequence of 
TeNT.
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of a co-crystallization study using the trisaccharide sialyl-
lactose suggest this site as ganglioside binding site in
BoNT/B (Swaminathan and Eswaramoorthy, 2000). No
additional information is available on ganglioside interac-
tion with BoNTs on the molecular level.
The goal of the present study is to identify similarities
and distinctions in ganglioside binding among TeNT and
BoNTs. We applied mass spectroscopy (MS) combined
with the use of site specific mutants to determine the
number and position of ganglioside binding sites in BoNT/
A and B. In addition, a mutational analysis study was
conducted to assess the contribution of various residues
within identified binding pockets of BoNTs to ganglioside
interaction via binding experiments and toxicity assays.
 
Results
 
A single molecule of ganglioside GT1b binds to 
H
 
C
 
A or H
 
C
 
B
 
Results of recent analyses employing MS and site
directed mutagenesis demonstrated that two ganglioside
molecules can bind simultaneously to the TeNT H
 
C
 
-frag-
ment and that both binding sites are required for the
establishment of toxicity (Rummel 
 
et al
 
., 2003). To exam-
ine whether the poisoning process of the closely related
BoNTs also involves the binding of more than one gangli-
oside molecule, we assembled H
 
C
 
-fragment/GT1b com-
plexes and determined their molecular weight by matrix
assisted laser desorption ionisation-time of flight (MALDI-
TOF) MS. The trisialoganglioside GT1b was chosen for
complex formation, as earlier experiments on BoNT/A and
B attributed highest binding affinities to this compound
(Kitamura 
 
et al
 
., 1980; Nishiki 
 
et al
 
., 1996b; Yowler 
 
et al
 
.,
2002). Measurements of wild-type H
 
C
 
-fragment of BoNT/
A and B provided m/
 
z
 
-values closely matching their theo-
retical masses and were thus used for internal calibration
(Fig. 3). Analyses of H
 
C
 
-fragment/GT1b mixtures resulted
in the detection of extra peaks with m/
 
z
 
-values of
53 876.6 Da, and 56 269.3 Da (indicated with * in Fig. 3B
and D), representing mass increases of 2000 Da and
2129 Da respectively. Gains in m/z are in close accord
 
Fig. 2.
 
 Upper panel: schematic drawing of BoNT and designation of its domains. The nicking site between LC and HC is depicted. The region 
forming the putative ganglioside binding site is highlighted by a green bar. Middle left and lower left panels show secondary structure presentations 
of BoNT/A and B H
 
C
 
-fragments, respectively. 
 
a
 
-Helices are presented as dark blue cylinders, 
 
b
 
-strands as light blue arrows, and residues subject 
of mutational analyses in this study and proposed to be involved in ganglioside binding are depicted in the stick model. Middle and lower right 
panels: Magnified illustration of the area framed in left panels.
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with the molecular mass of GT1b (2180 Da) and thus
provide evidence for the binding of one GT1b molecule to
each H
 
C
 
-fragment.
 
The sialyllactose interaction site in H
 
C
 
B and its 
counterpart in H
 
C
 
A are the sole sites that mediate binding 
to GT1b
 
In order to localize the sites involved in ganglioside bind-
ing within the H
 
C
 
-fragment of BoNT/A and B, we analysed
mutated H
 
C
 
-fragments. It is known from previous experi-
ments on TeNT that replacement of W1289 by leucine
disables the lactose binding pocket (Rummel 
 
et al
 
., 2003).
Alignment of the primary sequences of the CNT H
 
CC
 
-
domains indicates that W1266 and W1262 in BoNT/A and
B, respectively, are homologous to TeNT W1289 (Fig. 1).
We thus constructed mutants with a single amino acid
change, H
 
C
 
A-W1266L and H
 
C
 
B-W1262L, and determined
molecular weights of the mutants alone and after 30 min
of incubation with GT1b. Both mutants did not form H
 
C
 
-
fragment/GT1b complexes (Fig. 4). This study demon-
strates that only single sites are participating in carbohy-
drate binding. Amino acids surrounding W1262 in BoNT/
B have been previously identified as a binding site for
sialyllactose (Swaminathan and Eswaramoorthy, 2000)
and we recognized an equivalent cavity in BoNT/A
employing molecular modelling. We therefore conclude
that BoNT/A and B each possess only one carbohydrate
binding site, which is located in their H
 
CC
 
-domain and is
apparently homologous to the lactose binding site of
TeNT.
 
Recombinant H
 
C
 
A or H
 
C
 
B and the corresponding native 
full-length neurotoxins exhibit similar binding properties
 
As it cannot be excluded that recombinant H
 
C
 
-fragments
feature binding characteristics differing from the full-length
neurotoxins, we examined, whether they competed with
similar efficacy for the binding of radiolabelled BoNTs as
the corresponding native full-length neurotoxins. Figure 5
shows that unlabelled recombinant H
 
C
 
B and native BoNT/
B displaced with virtually identical potency the adherence
of 
 
125
 
I-BoNT/B to immobilized GT1b. Recombinant H
 
C
 
A
and native BoNT/A exhibit very similar efficacy in compet-
ing the binding of 
 
125
 
I-BoNT/A to GT1b (Fig. 5). Both H
 
C
 
A
and H
 
C
 
B competed with similar efficacy like the corre-
sponding native neurotoxins the attachment of 
 
125
 
I-BoNT
to synaptosomal membrane preparations, too (data not
shown). In fact, recombinant H
 
C
 
-fragments obviously
reflect the binding capacity of the corresponding native
full-length BoNTs.
 
The affinity of H
 
C
 
T to immobilized GT1b clearly exceeds 
that of H
 
C
 
A and H
 
C
 
B
 
In order to determine if the lack of the counterpart to the
 
Fig. 3.
 
 Binding of GT1b to wild-type H
 
C
 
-frag-
ments of BoNT/A and B assessed by MALDI-
TOF MS. Mass spectra of A and C show wild-
type H
 
C
 
A and H
 
C
 
B. B and D represent wild-type 
H
 
C
 
A and H
 
C
 
B, respectively, after incubation with 
20-fold molar excess of GT1b. Insets show the 
range of 53 000–57 000 (m/z; A, B) or 55 000–
59 000 (m/z; C, D) with different scaling of the 
 
y
 
-axis. Asterisks mark H
 
C
 
-fragment/ganglioside 
complexes. Extra peaks in the range of 57 220 
(m/z) represent unidentified impurities of the 
H
 
C
 
B preparation.
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TeNT sialic acid binding pocket in BoNTs leads to reduced
affinity in ganglioside interactions, we performed a com-
parative binding study. H
 
C
 
 fusion proteins, carrying car-
boxyl-terminal StrepTag motifs, were used to directly
compare H
 
C
 
-fragment binding affinities. H
 
C
 
T exhibited an
order of magnitude higher affinity compared to H
 
C
 
A and
H
 
C
 
B (Fig. 6). The use of H
 
C
 
T-R1226L, a mutant in which
the second ganglioside binding site of HCT was eliminated
without affecting the structural integrity of the molecule
(Rummel et al., 2003), allowed us to obtain information on
the affinity of the TeNT lactose binding pocket. The affinity
of HCT-R1226L to GT1b was only slightly lower than the
affinity of unaltered HCA or HCB (Fig. 6). This result was
confirmed by experiments employing synaptosomal mem-
brane preparations. Again HCT exhibited the highest affin-
ity and HCT-R1226L a slightly lower affinity compared to
Fig. 4. Binding of GT1b to mutated HC-frag-
ments of BoNT/A and B assessed by MALDI-
TOF MS. Mass spectra of (A) HCA-W1266L, 
and (C) HCB-W1262L. Mass spectra of B and 
D represent HCA-W1266L and HCB-W1262L, 
respectively, after incubation with 20-fold molar 
excess of GT1b. Insets show the range of 
53000–57000 (m/z; A, B) or 55000–59000 (m/
z; C, D) with different scaling of the y-axis. The 
peaks around of 57200 (m/z) represent an uni-
dentified impurity of the HCB-W1262L prepara-
tion. Note that no extra peaks were detectable 
upon incubation with ganglioside.
Fig. 5. Characterization of binding properties of 
recombinant BoNT HC-fragments. The binding 
of 125I-radiolabelled native BoNT/A or BoNT/B 
to ganglioside GT1b immobilized on microtitre 
plates was studied in the presence of various 
concentrations of unlabelled native neurotoxin 
or unlabelled recombinant HC-fragment. 125I-
BoNT/A plus BoNT/A (), 125I-BoNT/A plus HCA 
(), 125I-BoNT/B plus BoNT/B (H17009), 125I-BoNT/B 
plus HCB (D). Each data point represents the 
mean ± S.D. of three separate experiments 
each performed in duplicate. HCA and HCB dis-
place 125I-neurotoxins with similar efficiency as 
the respective native full-length BoNTs.
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HCA and HCB (data not shown; Rummel et al., 2003).
Thus, we conclude that the existence of a single ganglio-
side binding site in BoNTs explains their reduced affinity
to immobilized purified GT1b compared to HCT which has
previously been shown to include two binding sites (Rum-
mel et al., 2003).
Tyrosine and histidine in the binding pocket of HCA and 
HCB play a different role than the homologous residues in 
the TeNT HC-fragment
To assess the role of particular amino acids shaping the
binding pockets in interaction with ganglioside, we per-
formed a mutational analysis of the sialyllactose binding
site of BoNT/B and the corresponding binding pocket of
BoNT/A. Amino acids homologous to those of the lactose
binding site of TeNT were mutated. They are depicted in
their spatial configuration in Fig. 2. The effect of the vari-
ous mutations on the properties of BoNT were measured
employing three different assays. First, the ability of the
mutated full-length BoNTs to inhibit exocytosis at moto-
neurons was analysed employing the mouse phrenic
nerve (MPN) toxicity test. The measured paralytic half-
times and the corresponding toxicities of the various
mutants are presented in Table 1. The MPN toxicity assay
provides exact data especially for mutants with low affinity.
This may presumably relate to the lower availability of
receptor molecules at the MPN preparations and was
experienced earlier for mutants of TeNT as well (Rummel
et al., 2003). Second, the competency of mutated HC-
fragments to bind to nerve cell membranes was studied
employing rat brain synaptosome preparations (Fig. 7).
Binding of mutated radiolabelled HC-fragments to synap-
tosomal membranes proved to be specific, as it was sat-
urable, and the micromolar addition of recombinant wild-
type HC-fragment displaced radiolabelled molecules (data
not shown). Third, the ability to adhere to isolated gangli-
oside was measured by a microtitre well assay using
immobilized GT1b (Fig. 8). The effects of the individual
mutations on GT1b interaction, synaptosomal membrane
binding, and in MPN toxicity are strongly correlated.
Mutations designed to sterically block access to the
binding pocket, like the replacement of the imidazole side
Fig. 6. Comparative analysis of HCT (), HCT-R1226L (), HCA (), 
and HCB (H17009) binding to GT1b. 1 mg of ganglioside GT1b was immo-
bilized on microtitre plates and binding of HC-fragments was studied 
in low ionic strength buffer. Various amounts of bound HC-fragment 
were applied and the bound portions were detected using StrepTactin 
conjugated alkaline phosphatase. This reagent recognizes the 
StrepTag peptide motif fused in an identical manner to the carboxyl-
terminus of each of the HC-fragments, allowing the comparative 
assessment of binding.
Table 1. Activity of wild-type and mutated BoNT/A and B in the MPN toxicity assay.
Recombinant scBoNT
Paralytic halftime t1/2a min
661.8 pM Paralytic halftime t1/2a min
% Toxicity versus 
wild-type scBoNTb
scBoNT/A wild type 35.5 ± 5.0 100c
scBoNT/A E1203L 55.0 ± 2.8 17.4 ± 0.9
scBoNT/A S1264A 39.0 ± 1.4 63.3 ± 2.3
scBoNT/A W1266L 126.5 ± 7.8 0.7 ± 0.1
scBoNT/A Y1267F 101.5 ± 12.0 1.7 ± 0.2
scBoNT/A Y1267S 185.5 ± 6.4 0.2 ± 0.1
scBoNT/A H1253A 49.5 ± 6.4 25.9 ± 3.3
scBoNT/A H1253W n.d.d
1954 pM 6515 pM
scBoNT/B wild type 53.5 ± 4.9 100c
scBoNT/B E1189L 77.0 ± 1.4 27.5 ± 1.4
scBoNT/B E1190L >180 160.0 ± 2.8 0.5 ± 0.1
scBoNT/B S1260A >180 138.0 ± 1.4 0.9 ± 0.1
scBoNT/B W1262L >180 179.5 ± 3.5 0.3 ± 0.1
scBoNT/B Y1263F 154.5 ± 2.1 2.0 ± 0.1
scBoNT/B Y1263S >180 174.0 ± 8.5 0.4 ± 0.1
scBoNT/B H1241A 64.0 ± 5.7 28.0 ± 3.3
scBoNT/B H1241W >180 175.5 ± 15.7 0.4 ± 0.1
a. Data are means ± S.D. (n = 3–4).
b. To a five point concentration-response-curve each of wild-type scBoNT/A and B a power function was fitted (y (A) = 198.94x-0.2683, R2 = 0.989;
y (B) = 406.03x-0.2645, R2 = 0.988). For each mutant the correlative concentration of wild type was calculated and set in ratio.
c. Toxicity of wild type is set to 100%.
d. Not determined.
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group of H1253 in BoNT/A and H1241 in BoNT/B by the
bulky indole of tryptophan, consistently cause drastic
drops in binding affinity of HCA and HCB and in the toxicity
of BoNT/B. Recently it has been shown that the analogous
mutant of TeNT also lost binding affinity and neurotoxicity,
suggesting a similar overall geometry of the binding
pocket in TeNT and BoNTs (Rummel et al., 2003).
A strong effect on binding and toxicity is consistently
attained for both of the BoNTs by the substitution of the
indole ring of W1266 (W1262 in BoNT/B) by 2-methyl-1-
propyl and the removal of the phenyl ring of Y1267 (Y1263
in BoNT/B). Aliphatic replacement of the carboxyl group
of E1203 (E1190 in BoNT/B) and elimination of the
hydroxyl group of S1264 (S1260 in BoNT/B) severely
decrease binding affinity to GT1b and neuronal cell
membranes. In contrast, the mutation E1189L in BoNT/B
has only a minor effect on the functionality of the mole-
cule, as was found for mutation of the amino acid occu-
pying the corresponding position in TeNT, N1220 (Rummel
et al., 2003).
Interestingly, when binding pocket mutants of the
BoNTs and TeNT are compared, there are two remarkable
differences regarding interaction with gangliosides. The
hydroxyl group of TeNT Y1290 does not significantly con-
tribute to binding (Rummel et al., 2003), whereas the
mutation of the amino acids in BoNT/A and B diminishes
binding to synaptosomal membranes to 10.5% and 16.5%
of the wild-type binding, respectively, and toxicity to less
than 2%. The second difference occurs at the imidazole
ring of BoNT/B H1241 (H1253 in BoNT/A). In case of
BoNT/B, adherence to GT1b and synaptosomal mem-
branes was only reduced by ~ 50%, and BoNT/B H1241A
also has a high residual toxicity. In contrast, the corre-
sponding mutation of TeNT, H1271A, reduced the binding
affinity 10-fold and led to a nearly inactive molecule in
MPN toxicity assays. Thus, it appears that some of the
Fig. 7. Binding of in vitro translated 35S-labelled 
HC-fragment mutants to rat brain synapto-
somes. Binding experiments were performed in 
physiological buffer. Incubation was done for 
2 h at 0∞C. Washed pellet fractions were sub-
jected to SDS–PAGE, and the amount of bound 
[35S]-HC-fragment mutants was quantified by 
phosphor imaging and depicted as a percent-
age of wild-type binding. Black and grey 
columns refer to mutants of HCB and HCA 
respectively. Values for analogous HC-fragment 
mutants of the two serotypes are shown side 
by side. Data represent mean values ± S.D. of 
three independent experiments each per-
formed in triplicates.
Fig. 8. Binding of BoNT/A and B HC-fragment 
mutants to 1 mg ganglioside GT1b immobilized 
on microtitre plates in low ionic strength buffer. 
The amount of bound HC-fragments was deter-
mined using a StrepTag specific antibody, and 
illustrated as percentage of wild-type binding. 
Filled and open columns refer to mutants of 
HCB and HCA respectively. Values for analogous 
HC-fragment mutants of the two serotypes are 
juxtaposed. Data represent mean values ± S.D. 
of three to four independent experiments per-
formed in triplicates.
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amino acids within the TeNT lactose binding pocket inter-
act with ganglioside differently than the corresponding
residues within the BoNT pockets.
Spectroscopic structure analyses of mutated BoNT 
HC-fragments
To exclude the possibility that the individual mutations
had affected structural elements of the HC-fragment,
temperature-induced denaturing measurements employ-
ing circular dichroism (CD) spectroscopy were conducted.
Changes in the molar ellipticity at 220 nm were recorded
as a function of temperature. The scans of the wild-type
HCA and its mutants yielded steeply sigmoidal curves
(data not shown). Their melting temperatures (Tm), defined
by the inflection point, were between 48.3∞C and 49.2∞C,
virtually identical with a ±0.5∞C accuracy for measure-
ments. Hence, neither of the introduced mutations
impaired the structure of HCA. Corresponding analyses of
the structural integrity of mutants of HCB revealed two-
phase melting curves (data not shown). A contingent of
the protein melted between 44.5∞C and 49.7∞C. The
remaining structure denatured at 60.9–63.0∞C. Stepwise
melting was not observed for the HC-fragment mutants of
BoNT/A as described above nor of TeNT (Rummel et al.,
2003). Moreover, we found some variation in the ratio of
secondary structure loss for both phases for the same
HCB mutants among different preparations, whereas their
Tm-values kept constant. Because we experienced a
dependency on the protein concentration, both effects
may perhaps be ascribed to partial aggregation of mole-
cules. If so, the first phase could correspond to melting of
HC-fragment monomers and the second to denaturing of
aggregates. Focussing on the first phase, one mutant,
HCB-Y1263S, exhibited a Tm-value of 41.0∞C for the first
unfolding phase, being more than 5∞C lower compared to
the average Tm-value of all other mutants, whereas Tm of
the second unfolding phase did not diverge significantly.
Thus, Y1263 of BoNT/B appears to be critical for the
structural integrity of HCB, as was also found earlier for
the corresponding residue of TeNT (Y1290; Rummel
et al., 2003). The effect of this mutation on the activity of
the molecule must in part be attributed to local rearrange-
ments in the sialyllactose binding site. In contrast, the
phenyl ring of Y1267 of HCA likely contributes directly to
carbohydrate coordination, as its elimination did not affect
maintenance of the structure while drastically diminishing
binding and neurotoxicity.
Discussion
Ganglioside binding capacity of BoNTs
In the present study we provide evidence that BoNTs
unlike TeNT exhibit only a single ganglioside interaction
site in their HCC-domain. Analyses of HC-fragment/GT1b
mixtures by MS revealed that mutation of the sialyllactose
binding pocket of HCB and its counterpart in HCA abro-
gated their ability to form complexes with GT1b. Circular
dichroism measurements indicate that loss of binding was
not caused by structural alterations imposed by the muta-
tion. In contrast, experiments with the corresponding
mutant of TeNT, performed under identical experimental
conditions, demonstrated a second binding site. The sialic
acid binding pocket in TeNT showed a sufficiently high
affinity to be identified by MALDI-TOF MS (Rummel et al.,
2003). It is unlikely that a second carbohydrate binding
site was not detectable due to the preferred interaction of
BoNT-HC with a different ganglioside species, because
GT1b has been found to be the primary glycosphingolipid
receptor for BoNTs (Kitamura et al., 1980; Schengrund
et al., 1991; Lalli et al., 1999; Yowler et al., 2002).
Further support for the lack of a second ganglioside
binding site in BoNTs was provided by comparative bind-
ing experiments employing HCT, HCA and HCB. Wild-type
HCT showed approximately one order of magnitude higher
affinity to immobilized GT1b, whereas the mutant HCT-
R1226L, carrying a loss of function mutation in the sialic
acid binding site, bound via its intact lactose binding site
with an affinity slightly lower than that of HCA and HCB to
GT1b. In keeping with these findings are our results of
electrostatic surface plot inspections, which showed that
BoNT/A neither features a binding cavity at the position of
the TeNT sialic acid binding site nor has the capacity of
binding carbohydrate units at any other location within HC.
In case of BoNT/B, mutation of E1191 and K1192, resi-
dues located in positions comparable to the sialic acid
binding pocket in TeNT, did not cause changes in binding
characteristics (data not shown). It is thus unlikely that this
area had escaped detection as a ganglioside binding site
in MALDI-TOF MS studies as a result of too low affinity.
Contribution of individual amino acids to GT1b binding
Our study provides evidence that the three CNTs investi-
gated so far achieve coordination of the carbohydrate
ligand in an unique manner. Mutation of the tryptophan
and serine residues and removal of the phenyl group of
tyrosines (see Figs 1 and 2) dramatically affected the
functionality of all three neurotoxins. This was not surpris-
ing, as these amino acids are conserved among the bind-
ing pocket shaping residues in CNTs (Fig. 1). Tryptophan
is essential, forming strong ring stacking interactions with
the hydrophobic side of one sugar ring, in maintaining the
function of the ganglioside pocket. D1222 of TeNT repre-
sents apparently the counterpart of the glutamates 1203
and 1190 of BoNT/A and B respectively. Isosteric mutation
of these amino acids to those with aliphatic side groups,
Ganglioside binding of botulinum neurotoxins 639
© 2003 Blackwell Publishing Ltd, Molecular Microbiology, 51, 631–643
in all cases, strongly decreases ganglioside binding of HC.
This finding that D1222, E1203 and E1190 are key amino
acids in the binding of sugars is consistent with the doc-
umented H–bond interactions found in the HCT/GT1b-b
and BoNT/B/sialyllactose co-crystal structures (Swami-
nathan and Eswaramoorthy, 2000; Fotinou et al., 2001).
N1219 of TeNT interacts in addition to D1222 with the
distal (NAcGal) of the two coordinated sugar units in the
lactose binding site (Fotinou et al., 2001; Rummel et al.,
2003). Similarly, E1189 in the BoNT/B structure was
reported to shape an H-bond to O-2 of the distal sugar
unit (Gal; Swaminathan and Eswaramoorthy, 2000). How-
ever, the mutation of E1189 did not interfere much with
binding and only moderately with toxicity of the full-length
neurotoxin. Thus, we propose that E1189 in BoNT/B
rather corresponds to N1220 of TeNT, whose side group
according to mutational analyses and the HCT-GT1b-b co-
crystal structure points away from the binding cavity while
in contrast the amide side group of the adjacent N1219 in
TeNT is directed toward the ligand. It remains to be
shown, whether K1188 of BoNT/B can fulfil the role of
N1219 in TeNT.
A discrepancy shown in binding experiments among
TeNT and BoNTs pertains the role of tyrosine and histi-
dine. Where the hydroxyl group of tyrosine appears to be
redundant in HCT, its removal critically decreases gangli-
oside affinities of HCA and HCB. On the other hand, the
impact of the histidine on the functionality of the BoNT
binding pocket is less important compared to TeNT.
Because 3D-superimposition of C-a atoms of residues,
constituting this binding pocket, revealed a very similar
arrangement of the carbon backbone as well as of most
of the side chains in TeNT, BoNT/A, and B (data not
shown), the different roles of tyrosine and histidine have
to be ascribed to different interactions with carbohydrate
ligands. This conclusion is consistent with the recently
attained co-crystal structures of GT1b-b and sialyllactose
bound to TeNT-HC and BoNT/B respectively. The BoNT/B
binding pocket and its analogue in TeNT coordinate differ-
ent portions of the ganglioside carbohydrate structure
(Swaminathan and Eswaramoorthy, 2000; Fotinou et al.,
2001). The terminal Gal-NAcGal disaccharide of the gan-
glioside sugar backbone was found to occupy the TeNT
binding pocket, whereas a NAcNeu-Gal segment binds to
BoNT/B. Interestingly, the protruding glyceryl side group
of NAcNeu, that is not present in Gal, forms two H–bond
interactions with the hydroxyl group of Y1263, which may
therefore explain the prominent role of the tyrosine
hydroxyl group in BoNTs. In contrast, nitrogen ND-1 of
H1241 in BoNT/B keeps only one H–bond interaction with
the O-10 of the glyceryl group of NAcNeu whereas H1271
in TeNT forms simultaneously three H-bonds to different
oxygen atoms (O-4, O-5 and O-6) of the terminal Gal
(Fotinou et al., 2001). This explains the moderate influ-
ence on ganglioside binding upon removal of the H1241
imidazole ring in BoNT/B.
Hence, only the side groups of the aspartic/glutamic
acid and the strictly conserved tryptophan and serine in
the ganglioside binding pockets of TeNT, BoNT/A and B
similarly interact with common sugar structures of the
NAcNeu-Gal and Gal-NAcGal disaccharide portions of
GT1b.
The different binding mode does not compensate the lack 
of a second binding pocket in BoNTs
Although TeNT and BoNTs exhibit similar affinities to
nerve cell membranes, different binding affinities to gan-
gliosides were observed (Bakry et al., 1991; Nishiki et al.,
1994). Results obtained in this biochemical study support
the recent crystallographic finding that amino acids of the
identified single BoNT ganglioside binding pocket interact
with different carbohydrate portions compared to the anal-
ogous pocket in TeNT. These different binding modes
could presumably be ascribed to the limited degree of
freedom imposed on TeNT at the membrane surface by
its simultaneous binding to two glycosphingolipid mole-
cules derived of the same layer, whereas in case of
BoNTs the ganglioside might invade the binding pocket in
a steeper angle. The absence of either carbohydrate bind-
ing site in BoNTs is only on a minor level compensated
by the different nature of ganglioside binding within the
extant pocket.
It is well established that both, glycolipid and protein
receptors are crucial for high affinity binding to nerve cell
membranes (Halpern and Neale, 1995). As BoNTs and
TeNT bind with similar affinity (in the low nM range) to
those receptors, binding has to be interpreted as the
simultaneous occupation of the identified ganglioside
binding pocket by GT1b and of a yet to be localized
binding site for a proteinaceous ligand. This was approved
for the high affinity binding of BoNT/B, that depends on
the presence of synaptotagmin II and GT1b (Nishiki et al.,
1996a; Dong et al., 2003). In TeNT, the second adherence
site, the sialic acid binding pocket, probably interacts at a
later stage of the uptake process with the carbohydrate
portion of a glycoprotein co-receptor. A GPI-anchored
glycoprotein was indeed recently recognized as a supple-
mentary cell surface receptor for TeNT (Herreros et al.,
2001; Munro et al., 2001).
In conclusion, these results provide valuable informa-
tion for the development of effective binding inhibitors as
antidotes against botulism. Antidotes are urgently
needed, because currently hyperimmune sera from horse
affords the only chance to treat acute botulism. Serotype
specific peculiarities in the ganglioside binding mode of
TeNT, BoNT/A, and BoNT/B point out that inhibitors may
be unique for individual neurotoxins.
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Experimental procedures
Molecular modelling
Molecular modelling was done using an Octane workstation
(Silicon Graphics) and the Insight II 2000 software (Molecular
Simulations).
Plasmid constructions
Gene portions encoding the HC-fragments of BoNT/A (strain
62 A) and B (strain Okra) were fused to a double stranded
oligonucleotide coding for the StrepTag II (IBA GmbH) and
inserted into pQE3 (Qiagen) yielding the expression plasmids
pHCAS and pHCBS and into the transcription vector pSP72
(Promega). Mutations in the HC-fragments were generated by
PCR using suitable primers and pHCAS and pHCBS as tem-
plate DNAs. Nucleotide sequences of all mutants were veri-
fied by DNA sequencing. The plasmid encoding full-length
wild-type BoNT/A with carboxyl-terminal StrepTag (pBoN-
TAS) was constructed using pBN3 (encoding the LC, Binz
et al., 2002), pUC18bot13, pUC18bot320 (Binz et al., 1990)
and pHCAS. The plasmid encoding full-length wild-type
BoNT/B fused to a carboxyl-terminal StrepTag (pBoNTBS)
was assembled by ligation of fragments derived from LC- and
HC-specific plasmids and pHCBS. Corresponding mutated
full-length BoNT expression plasmids were generated by
swapping DNA fragments between pBoNTAS or pBoNTBS
and mutated pHCAS or pHCBS plasmids respectively. The
construction of equivalent TeNT-specific plasmids was
detailed earlier (Rummel et al., 2003).
Purification of recombinant proteins
Wild-type and mutated recombinant HC-fragments of BoNTs
and TeNT and full-length scBoNTs were produced as fusion
proteins with an carboxyl-terminal StrepTag utilizing the
E. coli strain M15pREP4 (Qiagen) during 10 h of incubation
at room temperature, and were purified on StrepTactin-
Superflow matrix (IBA GmbH) according to the manufac-
turer’s instructions. The carboxyl-terminal StrepTag was not
removed, as tagged HC-fragments and corresponding HC-
fragments with authentic carboxyl-termini exhibited indistin-
guishable properties in our binding assays. Fractions contain-
ing the desired proteins were pooled, frozen in liquid nitrogen,
and kept at -70∞C.
Mass determination of HC-fragment/GT1b complexes
Wild-type HCA, HCB and the mutants HCA-W1266L and HCB-
W1262L (1.6 mM) were incubated with or without 32 mM GT1b
in binding buffer (minus BSA) for 30 min at 37∞C. Aliquots
(5 ml) of each mixture were mixed in a 1:1 ratio with either of
the matrices of a saturated sinapinic acid solution or EAM-1
(Ciphergen Biosystems) in 50% acetonitrile-water containing
0.5% trifluoroacetic acid. Twice, 2 ml of each mixture were
dropped on a 8-spot gold surface chip and air-dried. Data
were collected by a surface enhanced laser desorption/ioni-
sation time of flight mass spectrometer (SELDI-TOF MS) PBS
II (Ciphergen Biosystems) and analysed with the Ciphergen
ProteinChip software 3.0.1.
Iodination procedure
Twenty micrograms of native BoNT/A and BoNT/B (#130 A
and #136 A, List Biological Laboratories) were radiolabelled
applying the lactoperoxidase method (Pearse and Gallagher,
1989). Labelling reactions proceeded for one hour at room
temperature in the presence of 60 MBq of carrier free Na125I
(>0.6 TBq/mg, Amersham Pharmacia Biotech), and 5 mg lac-
toperoxidase (ICN) in a total volume of 200 ml by stepwise
addition of a total of 60 ml of 3% H2O2. Non-incorporated 125I
was removed by ultrafiltration using Vivaspin 2 columns
(30000 MWCO, Vivascience) and BSA was then added as
stabiliser (0.1% final concentration). More than 85% radioac-
tivity of the radiolabelled BoNTs was precipitable with 10%
cold trichloroacetic acid. Specific activities were: BoNT/A,
194.4 MBq/mg; BoNT/B, 195.6 MBq/mg.
Binding to ganglioside GT1b
Ganglioside GT1b [NAcNeua3Galb3NAcGalb4(NAcNeua8
NAcNeua3)Galb4GlcbCer] (Sigma-Aldrich) was dissolved in
methanol and applied to high-affinity 96-well polystyrene
microtitre plates (Corning; 1 mg GT1b in 100 ml/well) or in
case of competition assays with 125I-BoNTs to high-affinity C8
single-break stripe plates (Greiner Bio-one; 0.1 mg GT1b in
100 ml/well). The solvent was evaporated at room tempera-
ture and wells were washed three times with binding buffer
(10 mM Tris-HCl, 10 mM Na2HPO4, 0.5% BSA, pH 7.2).
Unspecific binding sites were then blocked by incubating for
2 h in PBS/Tween buffer [140 mM NaCl, 7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4, 0.05% (v/v) Tween 20, pH 7.2]
supplemented with 3% (w/v) BSA.
Binding assays were performed in binding buffer (100 ml/
well) for 2 h at room temperature containing either increasing
amounts of wild-type HCA, HCB and HCT and the mutant HCT-
R1226L (0.2–200 mg) or fixed amounts (2.875 mg) of mutants
of HCA or HCB. Unbound protein was removed by three wash-
ing steps, each one with 250 ml of PBS/Tween buffer. Bound
HC-fragments were detected by incubation with StrepTactin
conjugated alkaline phosphatase (ST-AP, IBA GmbH) in bind-
ing buffer for 2 h at room temperature according to the man-
ufacturer’s instructions. p-Nitrophenylphosphate (1 mg ml-1 in
100 mM glycine, 1 mM MgCl2, 1 mM ZnCl2, pH 10.4) finally
served as the substrate for alkaline phosphatase. The
dephosphorylation reaction was stopped by adding 3 M
NaOH solution, and the extinction at 405 nm was scanned
employing a SpectraCount microplate reader (Packard).
Competition assays were conducted for 2 h at room tem-
perature in 100 ml binding buffer containing 700 000 cpm/well
of [125I]-BoNT, various amounts of either native BoNT or
recombinant HC-fragment. Subsequent to incubations and
removal of supernatants, wells were washed three times with
PBS/Tween buffer, dried, and separated. Amounts of bound
radiolabelled BoNT were then determined in an automatic g-
counter (Wallac 1480 Wizard 3).
In vitro transcription and translation
HC-fragments were synthesised in vitro from pSP72
derivatives that were previously linearized downstream of
the neurotoxins’ carboxyl-terminal codon using the re-
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ticulocyte lysate system (Promega) and L-[35S]-methionine
(555 KBq, >37 TBq/mmol; Amersham Pharmacia Biotech), in
a total volume of 25 ml.
Binding assay using rat brain synaptosomes
Binding of radiolabelled HC-fragments to rat brain synapto-
somes was studied as detailed in Rummel et al. (2003).
Briefly, functional synaptosomes were recovered from a Per-
coll gradient after homogenization of rat brain and various
centrifugation steps and finally diluted in physiological buffer
(140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 20 mM
Hepes, 10 mM glucose, 0.5% BSA, pH 7.4) with the final
synaptosomal protein adjusted to a concentration of
10 mg ml-1.
Binding assays were performed in triplicates, in a total
volume of 100 ml of physiological buffer for 2 h at 0∞C, con-
taining a 5 ml aliquot of the 35S-labelled HC-fragment (reach-
ing a final concentration of ~ 3 pM), or 700 000 cpm of [125I]-
BoNT and 30 ml of the synaptosome suspension. For com-
petition assays various amounts of the recombinant wild-
type HC-fragment or native BoNT were added. Controls were
performed with samples lacking synaptosomes. After incu-
bation, synaptosomes were collected by centrifugation
(5000 g; 5 min) and unbound material in the supernatant
fraction was discarded. The pellet fractions were washed
two times each with 50 ml of physiological buffer and incu-
bated for 30 min at 37∞C in SDS sample buffer or, in the
case of 125I-BoNT samples, directly subjected to g-counting.
[35S]-HC-BoNT samples were then analysed by SDS–PAGE,
together with a 5 ml aliquot of the in vitro translation mixture
to quantify the yield of radiolabelled protein. Bound 35S-radi-
olabelled HC-fragments were visualized using a BAS-1500
phosphor imager (Fuji Photo Film), and quantified applying
the Tina 2.09f software (Raytest Isotopenmeßgeräte
GmbH). Amounts of bound HC-fragments were calculated
after subtraction of the value obtained for control samples as
the percentage of the total HC-fragment protein in the assay,
and finally compared with the binding efficiency of the wild-
type HC-fragment.
Mouse phrenic nerve toxicity assay
The MPN toxicity assay was set up as described by Hab-
ermann et al. (1980). Electrical stimulation of the phrenic
nerve was continuously performed at a frequency of 1 Hz.
Isometric contractions were transformed with a force
transducer and recorded with the VitroDat Online software
(FMI GmbH). The time required to decrease the amplitude
to 50% of the starting value (paralytic halftime) was mea-
sured. Full-length wild-type scBoNT/A was applied in trip-
licate at final concentrations of 2.0 pM, 6.6 pM, 19.9 pM,
66.2 pM, 198.5 pM and 661.8 pM. A concentration-
response-curve was constructed described by the power
function y = 194.7x-0.2663 (R2 = 0.991). scBoNT/A mutants
were tested in triplicate at 661.8 pM final concentrations.
Full-length wild-type scBoNT/B was applied in triplicate at
final concentrations of 19.5 pM, 65.2 pM, 195.4 pM,
651.4 pM, 1954 pM. A concentration-response-curve was
obtained which may be described by the power function
y = 406.2x-0.2646 (R2 = 0.988). scBoNT/B mutants were
tested in triplicate at 1954 pM or 6515 pM final concentra-
tions. The resulting paralytic halftimes were converted to
corresponding concentrations of wild-type BoNTs, using
the equations mentioned above. Toxicities were finally
expressed as a percentage of wild-type activity.
The catalytic activity of the LC of all mutants was vali-
dated in in vitro cleavage assays employing the appropri-
ate substrates (data not shown).
CD spectroscopy
Circular dichroism data was collected with a Dichrograph III
(Jobin-Yvon) spectropolarimeter equipped with a computer
controlled temperature cuvette holder. Temperature-induced
denaturation was performed in 100 mM Tris-HCl buffer at a
protein concentration of 75 mg ml-1, by monitoring the CD
signal at 220 nm in a 4-mm path length cuvette. The temper-
ature increase of 0.9∞C min-1 from 25∞C to 80∞C was mea-
sured directly in the protein solution with a thermistor.
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Botulinum neurotoxins (BoNTs) induce muscle paral-
ysis by selectively entering cholinergic motoneurons
and subsequent specific cleavage of core components of
the vesicular fusion machinery. Complex gangliosides
are requisite for efficient binding to neuronal cells,
but protein receptors are critical for internalization.
Recent work evidenced that synaptotagmins I and II
can function as protein receptors for BoNT/B (Dong, M.,
Richards, D. A., Goodnough, M. C., Tepp, W. H., Johnson,
E. A., and Chapman, E. R. (2003) J. Cell Biol. 162, 1293–
1303). Here, we report the protein receptor for a second
BoNT serotype. Like BoNT/B, BoNT/G employs synapto-
tagmins I and II to enter phrenic nerve cells. Using
pull-down assays we show that only BoNT/G, but neither
the five remaining BoNTs nor tetanus neurotoxin, inter-
acts with synaptotagmins I and II. In contrast to BoNT/B,
interactions with both isoforms are independent of the
presence of gangliosides. Peptides derived from the lu-
minal domain of synaptotagmin I and II are capable of
blocking the neurotoxicity of BoNT/G in phrenic nerve
preparations. Pull-down and neutralization assays fur-
ther established the membrane-juxtaposed 10 luminal
amino acids of synaptotagmins I and II as the critical
segment for neurotoxin binding. In addition, we show
that the carboxyl-terminal domain of the cell binding
fragment of BoNT/B and BoNT/G mediates the interac-
tion with their protein receptor.
Clostridial neurotoxins (CNTs)1 are extremely potent bacte-
rial toxins. Among them, the seven serologically distinct botu-
linum neurotoxins (BoNTs, serotypes A-G) cause botulism,
whereas the tetanus neurotoxin (TeNT) provokes the disease
tetanus. Each neurotoxin is composed of four domains. Their
light chains (LCs) act as zinc-dependent endopeptidases and
specifically hydrolyze certain proteins of the vesicular fusion
machinery, whereupon the Ca2-triggered fusion of synaptic
vesicles with the presynaptic membrane is disrupted (reviewed
in Refs. 1–3). The heavy chains (HCs) are tethered to the LCs
via a single disulfide bond and encompass the three remaining
domains. The HC serves as the vehicle that delivers the LC to
the cytosol of neuronal cells. Therefore, the extreme toxicity
has to be largely ascribed to the specific binding of the molecule
to nerve terminals at the neuromuscular junction. The amino-
terminal segment of the HC, the HN domain, is responsible for
translocating the LC from the lumen of an acidic intracellular
compartment into the cytosol subsequent to cell binding and
receptor-mediated endocytosis. The carboxyl-terminal segment
of the HC, the so-called HC-fragment (HC), comprises two do-
mains, HCN and HCC. The latter was shown in the case of TeNT
to suffice for cell binding (4) and internalization (5). TeNT
travels retrogradely and eventually arrives at inhibitory inter-
neurons in the spinal cord where it provokes spastic paralysis.
So far, the corresponding domain has not been identified for
BoNTs, which in contrast act locally at motoneurons and cause
flaccid paralysis. No function could yet be attributed to the
HCN domain.
It has long been known that polysialogangliosides, i.e. glyco-
sphingolipids that are particularly enriched in the outer leaflet
of neuronal cell membranes, are crucial for the binding of CNTs
to neurons. TeNT and BoNTs exhibit affinities in the high nM
range for isolated polysialogangliosides. The binding of CNTs
to neuronal tissue, however, exhibits yet much higher affinities
(reviewed in Ref. 6). This discrepancy as well as other findings
led to the proposal of the now confirmed two-receptor model (7).
This model suggests that the abundant polysialogangliosides
trap and accumulate CNTs in the plane of the cell membrane.
Here, the neurotoxins wait until achieving contact with their
sparsely occurring protein receptor(s), which are assumed to
mediate the subsequent specific endocytosis. Synaptotagmin
(Syt)-I and Syt-II, two homologous membrane-anchored pro-
teins of synaptic vesicles (8, 9) thought to link vesicular fusion
to Ca2 entry (10, 11), were demonstrated to interact with
BoNT/B in the presence of GT1b (12–14). Recently, it was
conclusively shown that their luminal domain, which becomes
temporarily exposed at the synaptic cleft upon fusion of synap-
tic vesicles, interacts with BoNT/B and mediates the entry of
BoNT/B into neurons (15).
In the present study, we investigated whether other CNTs
than BoNT/B can utilize Syt-I or Syt-II as protein receptors.
Our results establish that BoNT/G interacts directly with both
Syt-I and Syt-II in a ganglioside-independent fashion. More-
over, neutralization studies employing peptides derived from
the luminal domain of Syt-I or Syt-II effectively block the
toxicity of BoNT/G in mouse phrenic nerve preparations. Thus,
the interaction of BoNT/G with Syt-I or Syt-II is crucial for its
entry into motor nerve terminals.
EXPERIMENTAL PROCEDURES
Plasmid Constructions and Recombinant Proteins—Plasmids encod-
ing full-length BoNT/A and BoNT/B as well as the HC-fragments of
TeNT, BoNT/A, and BoNT/B were described previously (16, 17). Corre-
sponding constructs for the expression of BoNT/C, -D, -E, -F, and -G
HC-fragments carrying a carboxyl-terminal StrepTag were generated
by using PCR with suitable primers and purified bacteriophage DNA
(BoNT/C and -D) or total bacterial DNA (BoNT/E, strain NCTC 11219;
* This work was supported by Grant RGY0027/2001 from the Human
Frontier Science Program (to T. B.). The costs of publication of this
article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
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1 The abbreviations used are: CNT, clostridial neurotoxin; BoNT,
botulinum neurotoxin; HC, heavy chain; HCC, carboxyl-terminal do-
main of the HC; HCN, amino-terminal domain of the HC; HN, amino
terminal half of the heavy chain; LC, light chain; scBoNT, single chain
BoNT; Syt, synaptotagmin; TeNT, tetanus neurotoxin; RT, room tem-
perature; GST, glutathione S-transferase.
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BoNT/F, strain NCTC 10281; BoNT/G (Clostridium argentinense)) as
template DNA. Plasmids for Escherichia coli expression of carboxyl-
terminal His6-tagged HCN and HCC domains of BoNT/A, -B, and -G were
constructed by PCR using suitable primers and pQE3 (Qiagen, Hilden,
Germany) as parental vector. A plasmid encoding full-length BoNT/G
with carboxyl-terminal StrepTag (pBoNTG-wt) was assembled from LC
and HN domain-encoding DNA pieces obtained by PCR in the HC-
encoding vector. An expression plasmid (pBoNTG-thro) for full-length
BoNT/G comprising a thrombin cleavage site between L and HN was
constructed in the same manner. Truncated variants of rat Syt-I (1–82,
1–53, 1–43), rat Syt-II (1–90, 1–61, 1–51), and rat Syt-III (1–80) were
cloned in pGEX-2T. Nucleotide sequences of all plasmids were verified
by DNA sequencing.
Recombinant full-length neurotoxins and the various HC-derived
fragments were produced utilizing the E. coli strain M15[pREP4] (Qia-
gen) during 10 h of induction at RT and purified on Strep-Tactin (IBA
GmbH, Go¨ttingen, Germany) or nickel-nitrilotriacetic acid beads (Qia-
gen) according to the manufacturers’ instructions. GST fusion proteins
obtained from E. coli TG1 were purified employing glutathione-Sepha-
rose beads. Fractions containing the desired proteins were pooled and
dialyzed against Tris/NaCl buffer (20 mM Tris-HCl, 150 mM NaCl, pH
7.2) or, in the case of neurotoxins, directly frozen in liquid nitrogen and
kept at 70 °C. GST fusion proteins used for pull-down experiments
were prepared in Tris/NaCl buffer supplemented with 0.5% Triton
X-100 (Tris/NaCl/Triton buffer).
Syt-I-1–53 and Syt-II-1–61 were also extracted from the respective
GST fusion proteins using the thrombin cleavage site present between
the GST and Syt sections by applying thrombin (Roche Applied Science)
in a 1:100 mass ratio for 2 h at RT. Thrombin was subsequently
inactivated using phenylmethylsulphonylfluoride.
GST Pull-down Assays—GST fusion proteins (0.14 nmol each) im-
mobilized to 10 l of GT-Sepharose beads were incubated with full-
length neurotoxins, HC-fragments, HCN or HCC domains (0.06 nmol
each) in the absence or presence of a bovine brain ganglioside mixture
(18% GM1, 55% GD1a, 10% GT1b, and 2% other gangliosides; 5 g each;
Calbiochem) in a total volume of 200 l of Tris/NaCl/Triton buffer for 90
min at 4 °C. Beads were collected by centrifugation and washed three
times each with 35 bed volumes of the same buffer. Washed pellet
fractions were boiled in SDS sample buffer and analyzed together with
supernatant fractions by SDS-PAGE and Coomassie Blue staining.
Mouse Phrenic Nerve Assays—The mouse phrenic nerve assay was
set up as described by Habermann et al. (18). Electrical stimulation of
the phrenic nerve was performed continuously at a frequency of 1 Hz.
Isometric contractions were recorded with a force transducer and ana-
lyzed with VitroDat Online software (FMI GmbH, Seeheim, Germany).
The time required to reduce the amplitude to 50% of the starting value
(paralytic half-time) was determined. Recombinant BoNT/G-thro was
applied in triplicate at final concentrations of 2.0, 6.0, 20.0, and 60.0 nM.
A concentration-response curve could be described by the power func-
tion y  128.13x0.2646 (R2  0.9838). A concentration-response curve
described by the power function y  69.11x0.2662 (R2  0.9855) was
obtained in the same manner for recombinant single chain BoNT/B
(scBoNT/B) applying final concentrations of 195.4, 651.4, and 1954 pM.
For inhibition studies scBoNT/A, scBoNT/B, and BoNT/G-thro were
mixed with various concentrations of Syt-I- or Syt-II-derived peptides,
incubated for 15 min at RT, and subsequently added to the hemidia-
phragm preparation. Paralytic half-times measured in the presence of
peptides were converted to corresponding concentrations of the respec-
tive isolated BoNTs using the equations mentioned above. Resulting
toxicities were finally expressed as percentage of inhibition of toxicity.
Individual inhibition experiments were conducted three to six times.
RESULTS
BoNT/G Directly Interacts with the Luminal Domain of Syt-I
and Syt-II—Previous studies demonstrated that Syt-I and
Syt-II interact with BoNT/B (12–14) and mediate its internal-
ization (15). In contrast, the entry of BoNT/A and BoNT/E does
not depend on the presence of Syt-I and Syt-II (15). To screen
whether any of the remaining CNTs utilizes interaction with
Syts to enter neuronal cells, we analyzed binding of their HC-
fragments to Syt-I and Syt-II in vitro. We conducted GST
pull-down experiments employing fusion proteins in which the
entire luminal and transmembrane domains of rat Syt-I and
Syt-II was fused to GST. As demonstrated in Fig. 1B, GSTSyt-
I-1–82 and GSTSyt-II-1–90 pull down the HC-fragments of
BoNT/B and BoNT/G. The finding with BoNT/B agrees with
results of Dong and colleagues (15); the finding with BoNT/G
constitutes a novel result. Binding of HCB and HCG to GSTSyt-
II-1–90 is saturable and reaches a 1:1 stoichiometry at satura-
tion (3-fold molar excess of HC; data not shown). We also
detected traces of HC-fragments of BoNT/A and BoNT/E pulled
down with GSTSyt-I-1–82 and GSTSyt-II-1–90 (Fig. 1B, ar-
rowheads). This interaction appears to be unspecific, as HCA is
pulled down to a similar extent by GSTSyb2 and GSTSyt-III-
1–80 (Fig. 1C), and probably explains data of a previous report
about the binding of BoNT/A and BoNT/E to Syt-I (19).
To substantiate the newly discovered BoNT/G-Syt interac-
tion, we studied the binding of the full-length neurotoxin as
well. For this, we constructed expression plasmids producing
BoNT/G fused to a carboxyl-terminal StrepTag. One variant
(scBoNT/G-wt) comprised the native loop region between the
two cystein residues that form the interchain disulfide bridge.
In a second variant (BoNT/G-thro), a recognition site for throm-
bin was inserted in this region at the expense of four of the
original amino acids (Fig. 2A). Both neurotoxin variants could
be isolated from E. coli lysates via their affinity tag and exhib-
FIG. 1. The HC-fragment of BoNT/G
binds to Syt-I and Syt-II. A, schematic
drawing of Syt. Syts are comprised of an
intraluminal, a transmembrane (TMD),
and two C2 domains (C2A, C2B). Syt con-
structs used in GST pull-down experi-
ments lacked the entire cytoplasmic part.
Numbers below specify amino acid posi-
tions of Syt-I and Syt-II. SV, synaptic ves-
icle. B and C, GST fusion proteins (5 g
each/reaction) immobilized on glutathi-
one-Sepharose beads were incubated for
90 min at 4 °C with CNT HC-fragments (3
g each) in the presence of gangliosides
(25 g/ml). Pellet fractions were washed
three times, and 20% of the material as
well as 2 g of each HC-fragment was
subjected to SDS-PAGE. Protein was sub-
sequently visualized by Coomassie Blue
staining. Asterisks denote breakdown
products of GST fusion proteins. Arrow-
heads point toward unspecifically bound
HCA and HCE.
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ited 85% purity (Fig. 2B). BoNT/G-wt was used for in vitro
binding studies as single chain protein. Full-length scBoNT/
G-wt also interacts with Syt-I and Syt-II, whereas no binding
was observed for scBoNT/A, underscoring that the pull down of
HCA is indeed unspecific (Fig. 3, middle panel).
It was recently shown that the interaction of BoNT/B with
Syt-I depends on the presence of gangliosides. Therefore, we
checked next whether BoNT/G displays the same binding
mode. However, BoNT/GSyt-I complexes already form in the
absence of gangliosides and exhibit a similar affinity as com-
pared with conditions with micelle-incorporated gangliosides
(Fig. 3, right panel).
BoNT/G Binds to the Membrane Proximal Region of Syt-I
and Syt-II—Because the mode of binding differs between
BoNT/B and BoNT/G with respect to the requirement of gan-
gliosides, it was interesting to investigate whether BoNT/B and
-G associate with the same segment of Syt. Dong et al. (15)
showed that the membrane proximal region of Syt-II, i.e. resi-
dues 40–60, comprises the binding site for BoNT/B. We there-
fore mapped the binding site for BoNT/G by truncating Syt-I
and Syt-II. Results presented in Fig. 4B show that HCG binds
to GSTSyt-II-1–61. No binding is detected, however, to
GSTSyt-II-1–51, suggesting that BoNT/G shares the interac-
tion site with BoNT/B. The binding site for BoNT/B in Syt-I
could not be determined via carboxyl-terminal-truncated Syt-I,
because this interaction only occurs when Syt-I and ganglio-
sides are concomitantly present in micellar structures (Fig. 4A)
(15). On the other hand, we were able to establish that the
corresponding membrane proximal segment of Syt-I, i.e. resi-
dues 43–53, is crucial for the binding of BoNT/G because HCG
is pulled down by GSTSyt-I-1–53 but not by GSTSyt-I-1–43.
This interaction occurs as with full-length BoNT/G-wt (Fig. 3)
whether gangliosides are present or not.
The Isolated Luminal Domain of Syt-I and Syt-II Blocks the
Toxicity of BoNT/G at the Mouse Phrenic Nerve—To provide
evidence for the physiological relevance of the BoNT/G-Syt
interaction, we investigated whether the neurotoxicity of
BoNT/G could be blocked by preincubating the neurotoxin with
peptides derived from the luminal domain of Syt-I and Syt-II.
As an assay system we chose the established mouse phrenic
nerve toxicity test (18). In the first set of experiments, we
inspected whether it succeeded in blocking the effect of
BoNT/B. scBoNT/B was applied in a 2-nM concentration, which
results in a 50% reduction of the hemidiaphragm muscle con-
tractile force within 59.2  3.6 min (paralytic half-time). Pre-
incubation of scBoNT/B with a 1000-fold molar excess of
GSTSyt-II-1–61 leads to a 61% inhibition of neurotoxicity (par-
alytic half-time: 76.0  5.7 min), whereas a 10,000-fold molar
excess results in a 95.1% inhibition (paralytic half-time:
132.3 13.2 min; Fig. 5). Removal of the GST portion increases
the potency of Syt-II-1–61 10-fold because a peptide concentra-
tion of 1.95 M raises the paralytic half-time to 138.5  10.6
min (corresponding to a 95.9% inhibition). In line with results
of the binding experiments, GSTSyt-II-1–51, a variant devoid
of the complete interaction site, has no influence on neurotox-
icity. Secondly, GSTSyt-I-1–53, as well as the corresponding
peptide Syt-I-1–53, does not significantly prolong the paralytic
half-time of scBoNT/B because preincubation occurred in the
absence of micellar gangliosides (Fig. 5).
BoNT/G proved to be far less active at the mouse phrenic
nerve than BoNT/B and BoNT/A, probably because of a lower
affinity to synaptosomal membranes2 as well as to a lower
catalytic activity of its LC versus other synaptobrevin-hydro-
lyzing CNTs (20). A final concentration of 105 nM scBoNT/G-wt
resulted in a paralytic half-time of 120 min (data not shown).
Bath concentrations of up to 1 mM GSTSyt would have been
required for inhibition studies. Attempts were undertaken to
acquire nicked, i.e. proteolytically activated, BoNT/G because
nicked CNTs are generally far more potent. However, activa-
tion of recombinant scBoNT/G-wt with trypsin leads to an
inadvertent hydrolysis of peptide bonds within the HC (Fig.
2B). To circumvent this problem, we utilized BoNT/G-thro,
which is to a great extent specifically activated by E. coli
proteases during the purification procedure. BoNT/G-thro
proves to be about 80-fold more active than scBoNT/G-wt. A
final bath concentration of 20 nM results in a paralytic half-
time of 55.8  3.8 min and was consequently used for neutral-
ization studies. In contrast to BoNT/B, both GSTSyt-II-1–61
and GSTSyt-I-1–53 are able to efficiently diminish the neuro-
toxicity of BoNT/G-thro on preincubation with a 1000-fold mo-
lar excess by 66.2% and 75.1% (according to 74.4  6.5 min,
80.7  2.5 min paralytic half-time), respectively. Syt-II-1–61
and Syt-I-1–53 applied at 100-fold molar excess decrease the
neurotoxicity by 37.9% (63.3  5.9 min) and 66.4% (74.5  4.9
min), respectively, and thus nearly approximate the efficacy of
their 10-fold higher concentrated GST-tagged variants. In ad-
dition, preincubation of BoNT/G-thro with an equimolar mix-
2 A. Rummel and T. Binz, unpublished results.
FIG. 2. Generation of full-length BoNT/G. A, expression plasmids
encoding BoNT/G carrying a carboxyl-terminal StrepTag comprised
either the native loop region between the LC and HC connecting cystein
residues (scBoNT/G-wt) or a thrombin cleavage site that was inserted
at the expense of four original amino acids (BoNT/G-thro). The recog-
nition site for thrombin is boxed, the scissile peptide bond indicated by
an arrowhead. B, SDS-PAGE analysis of purified recombinant BoNT/
G-wt and BoNT/G-thro before and subsequent to protease digestion by
trypsin (Tryp) or thrombin (Thro), respectively. Electrophoresis was
conducted under reducing conditions. Arrows point at the positions of
scBoNT/G, HC, and LC. The asterisk marks an uncharacterized neuro-
toxin byproduct, the arrowhead carboxyl-terminal breakdown products
of BoNT/G.
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ture of GSTSyt-II-1–61 and GSTSyt-I-1–53 (10 M each)
inhibits phrenic nerve paralysis to a similar extent as 19.5-M
concentrations of the individual fusion proteins (63.7%; 73.0 
2.8 min; Fig. 5). The shortened constructs GSTSyt-II-1–51 and
GSTSyt-I-1–43 do not affect the toxicity of BoNT/G-thro, as
indicated by paralytic half-times of 59.5  6.4 and 46.0  4.2
min, respectively, that do not significantly differ from the un-
treated control. The results with the latter truncated Syt vari-
ants also demonstrate that inhibition through GSTSyts is spe-
cific and does not interfere with any other physiological process
in the assay system. As a further control experiment, we as-
sessed whether the toxicity of scBoNT/A is effected by preincu-
FIG. 3. The binding of full-length BoNT/G to Syt-I does not depend upon the presence of gangliosides. Binding assays were conducted
as outlined in the legend to Fig. 1. However, binding assays were conducted partly in the absence of gangliosides. Asterisks denote breakdown and
byproducts of GST fusion proteins. Arrowheads indicate truncated Strep-tagged BoNT/G fragments that also bound specifically to GSTSyt-II-1–90.
These fragments are difficult to detect in GSTSyt-I-1–82, because they co-migrate with a byproduct of this fusion protein. Notably, BoNT/B does
not, but BoNT/G does interact with Syt-I in the absence of gangliosides.
FIG. 4. The membrane proximal
segment of Syt-I and Syt-II serves as
an interaction site for BoNT/G. Bind-
ing assays were performed as detailed in
the legend to Fig. 1, using the indicated
truncated versions of Syt-I (A) and Syt-II
(B). Upper panels represent experiments
done in the presence of 25 g/ml of gan-
gliosides (Gangl.); lower panels show
the results of corresponding experiments
without gangliosides (Gangl.). Asterisks
denote breakdown products of GST fusion
proteins.
FIG. 5. Preincubation of BoNT/G with luminal domain-derived Syt peptides blocks its neurotoxicity at the mouse phrenic nerve.
scBoNT/A, scBoNT/B (open columns), and BoNT/G-thro (filled columns) were preincubated for 15 min at RT with various amounts of truncated
GSTSyt-I, GSTSyt-II, or isolated Syt peptides as indicated. Mixtures were then added to electrically stimulated mice hemidiaphragm prepara-
tions, and isometric contractions were recorded and analyzed. The time required to decrease the amplitude to 50% of the starting value (paralytic
half-time) was determined as well as percent inhibition versus the respective untreated neurotoxin (for details see “Experimental Procedures”).
Synaptotagmins Act as Botulinum Neurotoxin G Receptor30868
bation with GSTSyt, because entry of this neurotoxin has
previously been shown to be independent of an interaction with
either Syt (15). As presented in Fig. 5, even a 19.5-M final
concentration of GSTSyt-II-1–61 has no detectable effect on
the toxicity of 0.22 nM scBoNT/A. This finding further validates
the specificity of the assay system. Together, these results
prove that Syt-I and Syt-II indeed do mediate the entry of
BoNT/G into peripheral nerve cells.
The HCC Domain of BoNT/B and BoNT/G Mediates the In-
teraction with Syt—It is known that the HCC domain of the
TeNT and BoNT HC-fragments is responsible for ganglioside
binding (17, 21, 22). No function could so far be allocated to
HCN. To assign the Syt binding site to either of the two do-
mains, we expressed each as His6-tagged proteins in E. coli and
conducted pull-down experiments. HCNA and HCCA served as
control peptides in this assay. Fig. 6 clearly demonstrates that
the HCC, but not the HCN, domain of BoNT/B and -G interacts
with GSTSyt-II-1–61. So, in addition to ganglioside binding,
the HCC domain of BoNT/B and BoNT/G mediates the interac-
tion with the protein receptor as well.
DISCUSSION
BoNTs, the causative agents of botulism, disrupt the neuro-
transmission of cholinergic nerves at the neuromuscular junc-
tion. More than one decade ago, the underlying molecular basis
for the inhibition of neurotransmitter release was deciphered
for all BoNTs and TeNT, which turned out to be the proteolysis
of one of three intracellular soluble NSF attachment protein
receptor proteins by their catalytic domains. On the other
hand, receptors that mediate the productive uptake of CNTs
into nerve terminals have so far only been unequivocally iden-
tified for BoNT/B (12, 15).
In this study, we have identified the cellular receptor for the
second of the eight CNTs, BoNT/G, which like BoNT/B is
guided into neurons through its specific interaction with Syt-I
or Syt-II. Two lines of evidence support this suggestion. First,
by means of GST pull-down experiments we were able to show
that BoNT/G interacts directly with the luminal domain of
Syt-I and Syt-II. Second, peptides derived from the luminal
domain of Syt-I and Syt-II are capable of blocking the entry of
BoNT/G into motoneurons that innervate the mouse dia-
phragm. This only occurs when these peptides contain the
membrane anchor-juxtaposed luminal 10 amino acids of Syt.
The identified segment of Syt-I and Syt-II becomes transiently
exposed on the membrane surface only when synaptic vesicles
fuse with the presynaptic membrane at synapses. This is in line
with the well documented finding that nerve stimulation gen-
erally accelerates the uptake of BoNTs and concomitant poi-
soning of nerve terminals (23). In a similar manner, TeNT was
previously also shown to be taken up via recycling of synaptic
vesicles (24). Together, these data suggest that CNTs in gen-
eral enter nerve terminals via this route and may associate
with segments of resident synaptic vesicle proteins that are
exposed to the luminal side.
In contrast to what was reported for BoNT/B (15), the bind-
ing of BoNT/G to Syt-I is apparently independent of the pres-
ence of gangliosides. The most obvious explanation for this
discrepancy is that a low affinity of BoNT/B for Syt-I does not
allow detection by GST pull-down experiments. Here, only the
simultaneous interaction with Syt-I and a ganglioside molecule
ultimately guarantees high affinity binding. In BoNT/G, se-
quence variation in its Syt binding fold may account for stron-
ger binding to Syt-I. Alternative explanations like the genera-
tion of a high affinity binding site for Syt-I because of
ganglioside-induced structural changes is unlikely to occur,
because significant structural changes were not observed in
several crystals of BoNT/B and its complexes with sialyllactose
(21) or doxorubicin (25). Furthermore, gangliosides incorpo-
rated in Triton micelles did not support binding of BoNT/B to a
truncated Syt-I variant that lacked the membrane anchor do-
main, indicating strict requirement of both Syt-I and ganglio-
side within the context of membranes.
Our study illustrates that the HCC domains of BoNT/B and
BoNT/G are responsible for the binding to their protein recep-
tor. This interaction is requisite for productive uptake into
neurons. Indirect evidence for an employment of HCC in this
process has recently been suggested for TeNT as well (5). Thus,
the HCC domains likely function as a closed cell entry module in
all CNTs, whereas the function of the HCN domain still awaits
elucidation.
The novel finding of the present study that BoNT/G, just like
BoNT/B, utilizes Syt-I and Syt-II for its entry into nerve ter-
minals is consistent with their degree of sequence conservation.
The similarity score for aligning their HC-fragments is 42.4%
and is only exceeded by the score of 58.0% for HCE (strain
NCTC11219)/HCF (Clostridium baratii) (ClustalW software).
Almost all other pairwise alignments result in less than 30%
similarity. We have further shown that the HCC domain of
BoNT/B and -G mediates the binding to Syt-I and Syt-II. With
respect to sequence alignments of HCC, HCCB/HCCG actually
reaches by far the highest similarity score (39.5%), whereas
those for many other pairs drop down to less than 20%. This
agrees with the notion that none of the remaining six CNTs
binds to Syt-I or Syt-II and the observation that BoNT/B and -G
are incapable of competing binding of BoNT/A and E to synap-
tosomal membranes. 2 These data add further support to the
premise that all other CNTs associate with different protein
receptors to become endocytosed. Interestingly, TeNT, which is
sorted into the retrograde axonal transport route upon endo-
cytosis, was demonstrated to bind simultaneously to two sep-
arate carbohydrate structures (16, 26), one of which could be
part of the recently discovered glycosylated 15-kDa protein
receptor (27). Therefore, the use of a separate protein receptor
that ensures exit from the lysosomal transport route of BoNTs
is plausible explicitly for TeNT.
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Summary and discussion 
Summary and discussion 
The isolation of HC-fragments from CNTs or their recombinant expression retains 
their full binding affinities. It is well established that CNT HC-fragments bind gangliosides, a 
class of glycosphingolipids that are found particularly in membranes of neuronal cells (van 
Heyningen and Miller, 1961; Simpson and Rapport, 1971b; 1971c). Deletion mutagenesis 
studies revealed that the TeNT HCC-domain binds to gangliosides and neuronal cells even 
more efficiently than the complete HC-fragment (Halpern and Loftus, 1993), whereas the HCN-
domain does not bind at all (Figueiredo et al., 1995). These results were amended in 
synaptosomal binding experiments employing 35S-labeled full length TeNT derivatives 
lacking either HC-fragment (LHNT), HCN-domain (LHNCCT) or HCC-domain (LHNCNT). Only 
LHNCCT bound to the rat brain synaptosomes as efficiently as isolated HC, HC-fragment and 
HCC-domain of TeNT (Rummel, data not shown). Moreover, the HCC-domain of TeNT 
constitutes the section that mediates retrograde intraaxonal transport in chicken spinal cord 
cells (Rummel et al., 2001) and, as demonstrated by cross-linking experiments, interacts with 
a GPI-anchored glycoprotein receptor (Herreros et al., 2000a). The HC-fragments of BoNT/A 
and B also consist of HCN- and HCC-domains folded similarly to the ones of TeNT (Lacy et 
al., 1998; Swaminathan and Eswaramoorthy, 2000), but not until recently the first isolated 
expression of the HCN- and HCC-domains of BoNT/A, B and G was achieved (Rummel et al., 
2004b). 
Thus, these studies suggest that the receptor binding sites of CNTs are localised within 
the HCC-domain. Although the HCN-domain displays a lectin-like fold, no carbohydrate 
binding to this segment is observed. Currently, it is unclear what role the HCN-domain plays in 
the intoxication mechanism. Hypotheses propose a function as a rigid, complex spacer 
between HN- and HCC-domain as well as an involvement in the translocation process. 
Characterisation of the ganglioside binding site in TeNT 
An early crosslinking experiment employing 125I-azido-GD1b and the TeNT 
HC-fragment led to radiolabeling of H1293 in the proximity of a large cavity within the HCC-
domain (Shapiro et al., 1997). The neighbourhood of H1293 to the ganglioside binding pocket 
was confirmed in a mutagenesis study showing reduced in vitro binding of the TeNT HC 
mutant H1293A to isolated ganglioside GT1b (Sinha et al., 2000). The mutation of the TeNT 
residue Y1290, forming the bottom of this cavity, to phenylalanine, serine and alanine also 
reduced the affinity to GT1b as well as the binding to synaptosomal membranes (J.M. Sutton 
et al., 2001). In computer-aided docking studies employing small molecules for inhibition of 
 50
Summary and discussion 
TeNT ganglioside binding, this cavity was chosen out of 52 other pockets possibly serving as 
ganglioside binding site. Into this pocket the anticancer drug doxorubicin, an anthracycline 
antibiotic, was docked thereby competitively inhibiting the binding of the TeNT HC-fragment 
to liposome-integrated GT1b (Lightstone et al., 2000). A cocrystallization of the TeNT 
HC-fragment and four carbohydrate subunits of GT1b exhibited four distinct binding sites, 
including the one in the proximity of H1293, where lactose interacts with the residues D1222, 
T1270, S1287, W1289, Y1290 and G1300. A separate site comprising R1226 as the key 
residue coordinated either a molecule of N-acetyl-galactosamine (NAcGal) or sialic acid 
(NAcNeu). Two additional sites were identified in cocrystals with galactose (Gal) or NAcGal 
(Emsley et al., 2000). However, the latter two sites are unlikely to function as binding pockets 
for polysialo gangliosides, due to insufficient space (Gal) or a high flexibility of the carbon 
backbone (NAcGal). Isaacs and coworkers refined their cocrystallisation approach by using a 
synthetic GT1b-β analogue lacking the ceramide portion. Indeed, the terminal disaccharide 
Galβ3GalNAcβ bound to the lactose binding site next to H1293 while the disialic acid branch 
of another GT1b-β molecule interacted with the sialic acid binding site comprising R1226 
(Fotinou et al., 2001). 
A detailed analysis of the lactose binding pocket of TeNT employing site directed 
mutagenesis revealed that binding of mutated HC-fragments to isolated GT1b as well as to 
synaptosomes was drastically reduced for each of the single mutations N1219I, D1222L, 
H1271A/W, S1287A/G, W1289G/L/V and Y1290A/F/S (Rummel et al., 2003). These data is 
in line with reduced binding of TeNT HC-fragment mutants D1222A, H1270A and W1289A 
to GT1b in surface plasmon resonance experiments and NGF differentiated PC12 cells 
(Louch et al., 2002). The physiological importance of the lactose binding site in TeNT was 
demonstrated by the application of corresponding, recombinant full length TeNT mutants at 
the mouse phrenic nerve assay leading e.g. to a 350 fold reduction in neurotoxicity in case of 
the single amino acid mutation W1289L (Rummel et al., 2003). 
Furthermore, the sialic acid binding site is essential for TeNT action as well. The 
TeNT HC-fragment mutants G1215F and R1226F/R showed weak binding to GT1b and to 
synaptosomes, and the full length mutant TeNT R1226F only retained 1.4 % of TeNT 
wildtype activity in the mouse phrenic nerve (MPN) assay (Rummel et al., 2003). These 
results are lately supported by independent cocrystallisations of TeNT HC-fragment with 
disialyllactose (NAcNeuα8NAcNeuα3Galβ4Glcβ), a GD3 derivative deficient of the 
ceramide portion, and with the tripeptide YEW which showed each of the ligands bonded in 
the sialic acid binding site (Jayaraman et al., 2005). 
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The presence of two neighbouring carbohydrate binding sites in the TeNT 
HCC-domain provoked the question whether a single molecule of GT1b is able to bind in a 
bidentate manner with its two sugar termini into the two ganglioside pocket. Such a binding 
mode can be observed in cholera toxin (CT) which coordinates five GM1 molecules in its five 
B-subunits via two interaction sites (Merritt et al., 1994). But according to the cocrystal of 
TeNT HC-fragment/GT1b-β (Fotinou et al., 2001), the surface distance between both pockets 
is too long for the length of the disialic acid branch of GD1b and GT1b (Rummel; 
computational analysis). MALDI-TOF mass spectroscopy (MS) allows the detection of 
ligands bound to the HC-fragment due to an increase of the molecular weight by 2.2 kDa. 
Indeed, the experiments indicated the simultaneous binding of two molecules GT1b to the 
TeNT HC-fragment. If binding of GT1b to either sites is blocked by a single aa substitution, 
only one bound molecule of GT1b was detected. Thus, two gangliosides can independently 
occupy the two ganglioside binding sites in TeNT (Rummel et al., 2003). Although binding of 
a ganglioside to the sialic acid binding pocket was shown, its subsequent substitution by or an 
initial interaction with the reported GPI anchored glycoproteins is conceivable. The binding of 
the tripeptide YEW to the sialic acid site supports this assumption (Jayaraman et al., 2005). 
At present, it is still unclear whether the two ganglioside binding sites of TeNT are a 
peculiarity of this neurotoxin and whether it relates to its retrograde intraaxonal transport. 
Characterisation of the ganglioside binding site in BoNT/A and B 
An alignment of the aa sequences of the HCC-domains (Tab. 2) reveals an identity of 
only 24%. Nevertheless, according to sequence alignment the lactose binding site 
characterised by the presence of the peptide motif H.....SXWY.....G is conserved among the 
majority of CNTs. This cavity displays the typical features necessary for carbohydrate 
interaction found also in other protein toxins like ricin and cholera toxin. An aromatic residue, 
preferable tryptophane or tyrosine, supplies the surface for the hydrophobic face of the sugar 
ring. Polar residues like glutamate, serine or asparagine are oppositely located to interact with 
the sugar hydroxyl groups (Hirst et al., 2002). Also, the results of cocrystallisation studies 
with BoNT/B and either sialyllactose (NAcNeuα3Galβ4Glcβ), which mimicks the sugar 
portion of GM3, or doxorubicin, respectively, suggest that the homologous lactose site in 
BoNT/B acts as ganglioside binding pocket (Swaminathan and Eswaramoorthy, 2000; 
Eswaramoorthy et al., 2001). 
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Table 2: The aa sequence identities of 18 CNT HC and HCC (http://align.genome.jp). 
HC HCC 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
1 BoNT/A Hall 62A 100 90,7 24,5 24,0 25,0 18,7 15,8 19,3 16,3 31,9 31,5 31,0 37,3 34,8 35,4 39,6 19,1 22,1
2 BoNT/A Kyoto-F inf. 87,2 100 24,5 24,0 26,0 20,2 15,3 20,8 15,8 32,4 32,1 32,1 37,3 34,2 35,9 39,6 21,6 21,6
3 BoNT/B 32,6 31,2 100 98,6 90,6 19,2 17,9 19,3 18,4 24,3 24,5 23,4 22,8 22,0 24,0 25,0 42,1 25,2
4 BoNT/B Isol. 1436 33,3 31,4 95,2 100 91,0 19,7 17,9 20,3 18,4 24,3 24,5 23,4 23,3 21,9 24,5 25,0 41,6 25,2
5 BoNT/B inf./111 34,4 34,2 92,0 91,3 100 19,2 18,4 19,8 18,4 24,9 25,0 23,9 24,4 21,4 24,5 26,0 43,1 25,2
6 BoNT/C1 Phage 22,8 23,7 21,5 21,9 25,6 100 24,0 57,4 23,0 17,8 17,4 17,4 17,1 15,5 18,8 18,8 19,2 15,7
7 BoNT/C Isol. 6813 24,2 24,6 25,8 26,2 29,4 33,6 100 23,0 93,4 18,4 19,0 19,0 19,2 19,3 19,8 16,1 19,9 16,3
8 BoNT/C/D 22,6 23,7 22,0 21,8 25,3 74,9 33,6 100 21,9 18,4 17,4 17,9 13,5 14,4 14,6 16,1 19,8 17,3
9 BoNT/D Phage 24,6 25,6 26,1 26,1 29,6 32,9 94,5 33,4 100 18,9 19,0 19,0 19,2 18,2 19,3 15,6 19,9 16,3
10 BoNT/E Beluga 37,7 36,4 24,0 24,5 28,3 21,5 21,3 20,5 20,8 100 98,4 95,1 45,9 41,6 44,3 48,6 18,4 17,3
11 BoNT/E NCTC11219 39,0 38,0 23,7 24,6 26,9 22,0 21,0 20,7 20,2 98,0 100 96,7 44,0 39,7 42,4 47,3 19,6 17,4
12 BoNT/E C Butyricum 37,7 36,4 23,7 24,0 26,7 22,0 21,8 20,8 21,3 97,3 96,6 100 44,0 39,7 42,4 47,3 19,0 14,6
13 BoNT/F NCTC10281 42,6 41,6 25,4 25,6 30,6 21,9 22,0 17,6 21,6 54,8 56,8 55,3 100 78,6 82,3 75,0 21,2 14,5
14 BoNT/F CDC3281 35,8 35,4 24,1 24,4 28,7 18,7 20,4 18,7 20,4 50,6 52,2 51,1 81,4 100 87,7 63,1 19,8 15,8
15 BoNT/F 202F 36,3 33,2 25,1 25,1 28,8 21,3 18,7 18,7 19,0 49,9 51,5 50,4 78,0 91,0 100 66,1 20,8 17,7
16 BoNT/F C.Baratii 43,6 42,2 27,1 26,9 30,9 22,2 22,0 19,6 21,6 56,5 58,0 56,7 78,5 70,0 67,1 100 21,9 18,2
17 BoNT/G 32,6 32,1 42,4 42,7 46,6 23,3 26,1 23,7 26,8 26,7 27,1 26,7 29,6 26,7 26,1 29,2 100 22,3
18 TeNT 24,2 24,0 23,4 23,4 26,6 18,0 18,7 18,1 18,7 21,8 22,2 22,0 18,8 19,7 20,1 21,7 25,1 100
 
The putative ganglioside binding sites of BoNT/A and B, the most important serotypes 
with respect to human botulism and use as pharmaceuticals, were in depth analysed to define 
the individual contribution of various residues within the homologous lactose binding pocket 
(Rummel et al., 2004a). The HC-fragment single mutants E1203L (E1190L), H1253W 
(H1241W), S1264A (S1260A), W1266L (W1262L) and Y1267F/S (Y1263F/S) of BoNT/A 
(BoNT/B) showed a drastic reduction in binding to GT1b as well as to synaptosomes. Despite 
of a similar pocket geometry, the residues histidine and tyrosine of BoNT/A and B display 
reverse effects compared with results obtained from TeNT indicating a different binding 
mode of the ganglioside (Rummel et al., 2004a). This idea is supported by comparison of the 
cocrystallisations of TeNT HC/GT1b-β and BoNT/B/sialyllactose (Swaminathan and 
Eswaramoorthy, 2000; Fotinou et al., 2001). In the former the terminal Gal interacts with the 
tryptophane and the NAcNeu sticks out of the pocket while in the latter the terminal NAcNeu 
binds directly to the tryptophane. However, the mutations of the aromatic key residues, 
W1266L and W1262L in BoNT/A and B, respectively, lead to a drastic reduction of 
neurotoxicity in the MPN assay as in case of TeNT (Rummel et al., 2004a). 
In contrast to TeNT, MS data revealed the binding of only a single GT1b molecule to 
the wildtype HC-fragment of BoNT/A and B. Upon deletion of the characterised ganglioside 
binding pocket via single mutations, ganglioside binding was no longer detectable in MS 
(Rummel et al., 2004a). Thus BoNT/A and B only possess one ganglioside binding pocket. 
Until now the crystal structures of the remaining BoNT serotypes are unknown. These 
structures can be predicted subsequent to a correct sequence alignment with an experimentally 
solved crystal structure used as template. If the template shares a sequence identity of >35% 
with the target protein, the root mean standard deviation of the prediction will be < 1.5 Å 
which is in the range of experimentally solved structures (http://swissmodel.expasy.org). 
According to Table 2 the aa sequences of the HCC-domains of BoNT/E and F are 32% and 
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36% identical to the known BoNT/A HCC-domain as well as the BoNT/G HCC-domain 
identity is 43% compared with HCC BoNT/B thus allowing a structure prediction. The aa 
sequences of BoNT/C1 and D deviate too much from the other serotypes to allow an accurate 
tertiary structure prediction. In general, the knowledge of the tertiary structure e.g. derived 
from computational predictions allows a rational approach of analysing the binding sites of 
the remaining BoNTs  
 
Fig. 9: Analysed residues forming the ganglioside binding sites in the known crystal 
structures of TeNT (A), BoNT/A (B), BoNT/B (C) and correspondingly the predicted 
positions of residues forming the putative ganglioside binding pockets in BoNT/E (D), 
BoNT/F (E) and BoNT/G (F). 
The predicted positions of residues forming the putative ganglioside binding pockets 
in BoNT/E, F and G are highly similar to the corresponding aa in BoNT/A and B, respectively 
(Fig. 9). E.g., the key residue tryptophane is found in all six serotypes at similar positions. 
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Hence, a homologous role of this cavity in BoNT/E, F and G as a ganglioside binding site is 
very likely. This is exemplified by the drastically reduced neurotoxicity (2.5% versus 
wildtype) of the full length BoNT/G mutant W1268L in the MPN assay (Rummel; data not 
shown). Thus, a single design of a potent inhibitor of ganglioside binding of CNTs might 
cover the requirements of all serotypes apart from BoNT/C1 and D. Their low degree of 
similarity hampers a successful prognosis, but a binding of a somewhat carbohydrate related 
structure in the HCC-domain is very likely since the HC-fragment of BoNT/C1 shows the 
highest binding to synaptosomal membranes (Rummel; data not shown). 
Characterisation of the protein receptor of BoNT/G 
As mentioned earlier (Tab. 2), the HC-fragment of BoNT/G shares 43% sequence 
identity with that of BoNT/B. Thus, BoNT/G might employ a protein receptor similar to that 
of BoNT/B which is Syt-I and Syt-II (Dong et al., 2003). GST-fusion-proteins of the 
intravesicular domain of Syt-I and Syt-II were generated to allow the analysis of BoNT/G-
Syt-I/II interactions in GST-pull-down assays. Indeed, of all CNT HC-fragments tested, only 
those of BoNT/B and G showed binding to GST-Syt-I 1-82 and GST-Syt-II 1-90 in the 
presence of micelle incorporated gangliosides. In the absence of gangliosides the BoNT/B 
interaction to Syt-I 1-82 was undetectable while the binding of BoNT/B to Syt-II 1-90 and 
BoNT/G to Syt-I 1-82 and Syt-II 1-90 was reduced, respectively. The interacting domains of 
Syt-I and Syt-II could be ascribed to the membrane juxtaposed 20 aa. This interaction was 
physiologically verified by the inhibition of neurotoxicity of scBoNT/B and BoNT/G in the 
MPN assay upon addition of the intravesicular domain peptides of Syt-I and Syt-II (Rummel 
et al., 2004b). Thus, it is likely that the remaining BoNTs similarly employ a protein receptor 
localised in synaptic vesicles and presenting an intravesicular domain. 
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Dual receptor mechanism of BoNTs 
If BoNTs do not possess a second carbohydrate binding site unlike TeNT, the question 
arises, whether the protein receptor like Syt-II for BoNT/B binds in the pocket homologous to 
the sialic acid site of TeNT. The interaction of the HCC-domain of BoNT/B and G with Syt-II 
supports this idea (Rummel et al., 2004b). Although both binding sites would be in proximate 
distance they could function independently and do not require preformation of a 
ganglioside/protein receptor complex. By confirming this assumption the dual receptor 
hypothesis by Montecucco would be proven (Montecucco, 1986). 
 
Fig. 10: Mechanism of binding and uptake of BoNTs (Courtesy of T. Binz). 
The current understanding of the mechanism of BoNT uptake into motoneurons is 
displayed in figure 10. The widely distributed polysialo gangliosides accumulate the BoNT 
molecule via a low affinity interaction on the surface of motoneurons. Upon exocytosis of 
neurotransmitters the intravesicular domain of a synaptic vesicle protein receptor is exposed 
extracellularly. The approach of the sparsely occurring protein receptor by the BoNT is 
facilitated due to the two dimensional movement of the ganglioside/BoNT complex within the 
plasma membrane. Following formation of a high affinity protein receptor/BoNT complex 
uptake is mediated. With the knowledge of both receptors types as well as the characterisation 
of binding sites within the HCC-domain of BoNTs the design of very potent bidentate 
antagonist is feasible and would allow the therapeutic treatment of acute BoNT intoxications. 
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